Bispecific antibody, pharmaceutical composition, and use
Patent Information
- Application Number
- MYPI2025005999
- Authority / Receiving Office
- MY · MY
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-03-29
- Filing Date
- 2024-03-29
- Publication Date
- 2024-09-29
AI Technical Summary
It is difficult to effectively relieve the suppression of immune effector cells by the tumor microenvironment with existing technology. In particular, LAG3 and CD73 are highly expressed in tumor treatment, resulting in immune evasion and poor therapeutic effect.
Develop a bispecific antibody that targets LAG3 and CD73. By blocking the binding of LAG3 to MHC-II and inhibiting the enzymatic activity of CD73, it relieves immune suppression and promotes T cell activation and IFN-γ secretion.
Significantly inhibits tumor growth, improves immune response, enhances anti-tumor therapeutic effects, and effectively prevents and treats various types of cancer.
Smart Images

Figure PI2025005999_DRAWING_001 
Figure PI2025005999_DRAWING_002 
Figure PI2025005999_DRAWING_003
Abstract
Description
Bispecific antibodies, pharmaceutical compositions and uses
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application is based on the application with CN application number 202310327266.6 and application date March 29, 2023, and claims its priority. The entire content of the CN application is hereby introduced as a whole into this application. Technical Field
[0003] The present invention belongs to the field of biomedicine and relates to a bispecific antibody, a pharmaceutical composition comprising the bispecific antibody, and uses thereof. Background Art
[0004] Tumors, especially malignant tumors, are a serious threat to human health worldwide, ranking second among all causes of death from various diseases. Furthermore, their incidence has shown a significant upward trend in recent years. Malignant tumors are poorly treated, have a high rate of late-stage metastasis, and often have a poor prognosis. While conventional treatments currently used in clinical practice, such as radiotherapy, chemotherapy, and surgery, have significantly alleviated pain and prolonged survival, these methods all have significant limitations, making further improvement in their efficacy difficult.
[0005] Lymphocyte-activation gene 3 (LAG3), also known as CD223, is a type I transmembrane protein composed of 498 amino acids and belongs to the immunoglobulin superfamily (IgSF). LAG3 is mainly expressed in activated CD4 + T cells and CD8 + LAG3 is also expressed by T cells, natural killer (NK) cells, B cells, regulatory T cells (Treg), and plasmacytoid dendritic cells (pDC). (Ruffo Elisa, Wu Richard C, Bruno Tullia C et al. Lymphocyte-activation gene 3 (LAG3): The next immune checkpoint receptor. [J]. Semin Immunol, 2019, 42: 101305.)
[0006] The LAG3 gene is located on human chromosome 12 (20p13.3), adjacent to the CD4 gene, and the two share identical exons and introns. Although their amino acid sequence homology is only approximately 20%, LAG3 and CD4 share a high degree of structural similarity. Major histocompatibility complex class II (MHC-II), liver sinusoidal endothelial cell lectin (LSECtin), and galectin-3 are ligands for LAG3. MHC-II is the primary ligand for LAG3, with an affinity for MHC-II (Kd: 60 nmol·L-1) that is 100-fold higher than that for CD4, indicating that LAG3 can effectively compete for CD4 binding to MHC-II, thereby inhibiting T cell activation.
[0007] In the tumor microenvironment, the expression of the immunosuppressive molecule LAG3 can be detected 24 hours after T cell activation, which leads to T cell dysfunction or apoptosis. LAG3 molecules form dimers with CD4 through their D1 domain (containing a proline-rich ring structure). + The specific binding of MHC-II molecules in the first signal axis of T cell activation "CD3-TCR-MHC-II" blocks the signal transduction pathway of T cell activation on the one hand, and on the other hand, the intracellular segment of the LAG3 molecule (KIEELE motif) generates immunosuppressive signals to downregulate CD4 + T cell activity. LAG3 can promote Treg cell differentiation and participate in signal transducer and activator of transcription 5 downstream signaling, thereby enhancing the inhibitory effect of Treg cells. This is one of the mechanisms by which tumors evade immune system killing (Andrews Lawrence P, Marciscano Ariel E, Drake Charles G et al. LAG3 (CD223) as a cancer immunotherapy target. [J]. Immunol Rev, 2017, 276: 80-96.).
[0008] Several studies have shown that LAG3 plays an important role in the tumor-infiltrating CD8 + Overexpression in T cells. For example, in ovarian cancer, tumor-infiltrating New York esophageal squamous cell carcinoma 1 antigen (NY-ESO-1)-specific CD8 + T cells express high levels of PD-1 and LAG3, which reduces the ability to produce IFN-γ and TNF-α, leading to lymphocyte inactivation. Galectin-3 and LSECtin mainly interact with LAG3 to regulate CD8 +T cell activation and function. Furthermore, melanoma antigen-specific T cells isolated from patients with melanoma metastasis showed significant upregulation of LAG3 and other immune checkpoint molecules, including CTLA-4 and TIM-3. (Liu Hao, Li Xinying, Luo Longlong, et al. Research progress on the molecular biological function of lymphocyte activation gene 3 and its clinical application in antibody drugs [J]. Chinese Journal of Pharmacology and Toxicology, 2019, 33(01): 70-78.)
[0009] Currently, a variety of LAG3 antibody drugs have entered the clinical research stage. Among them, Bristol-Myers Squibb's Relatlimab has made the fastest progress. It has conducted 10 clinical studies so far. Most of them are combined with Relatlimab and nivolumab for the treatment of tumors such as hematological malignancies, melanoma, glioblastoma, renal cell carcinoma and non-small cell lung cancer.
[0010] Ecto-5'-nucleotidase (CD73 protein) is a multifunctional glycoprotein with a molecular weight of 70KD encoded by the NT5E gene. It is anchored to the cell membrane through glyocsylphosphatidylinositol (GPI) (Zimmermann H. Biochem J. 1992; 285: 345–365).
[0011] CD73 is widely distributed on the surface of human tissue cells. Current studies have shown that CD73 is highly expressed in various solid tumors, including cancer cells, dendritic cells, regulatory T cells (Tregs), natural killer cells (NK cells), myeloid-derived suppressor cells (MDSCs), and tumor-associated macrophages (TAMs) within the tumor microenvironment. A key characteristic of the tumor microenvironment is hypoxia, which induces upregulation of molecules such as hypoxia-inducible factor-1 (HIF-1), leading to widespread expression of CD73 in the tumor microenvironment (Synnestvedt K, et al. J Clin Invest. 2002;110:993–1002). Analysis of clinical tumor samples has shown that high CD73 expression is a potential biomarker that is closely associated with poor prognosis in multiple tumor types, including breast, lung, ovarian, renal, gastric, and head and neck cancers.
[0012] CD73 has both hydrolytic and non-hydrolytic activities. These enzymatic and non-enzymatic functions coexist in tumor-related processes, mutually promoting each other and maintaining tumor progression. A growing number of studies have identified CD73 as a key regulator of tumor cell proliferation, metastasis, and invasion in vitro, as well as tumor angiogenesis and immune escape in vivo. A key immunosuppressive mechanism is mediated by the CD73-adenosine metabolic signaling pathway. CD39, upstream of CD73, catalyzes the conversion of ATP to adenosine monophosphate (AMP). This AMP is converted by CD73 to adenosine, which then binds to the downstream adenosine receptor (A2AR). The A2AR activates protein kinase A (PKA) and Csk kinase, inhibiting a series of immune activation-related signaling pathways, including LCK, MAPK, and PKC. This inhibits T cell immune cytotoxicity, thereby exerting immunosuppressive effects and enabling tumor immune escape (Antonioli L, et al. Nat Rev Cancer. 2013;13:842–857). Preclinical animal model studies have shown that CD73 expressed by both immune cells and non-immune cells can promote tumor immune escape, development and metastasis, among which Treg cell-related CD73-adenosine signals have the most significant inhibitory effect on CTL (cytotoxic T cells) and NK cell functions.
[0013] For solid tumor treatment, overcoming drug resistance and improving efficacy is crucial for overcoming the inhibitory effects of the tumor microenvironment (TME) on immune effector cells. The TME is a complex system composed of diverse cells, extracellular matrix, enzymes, cytokines, and metabolic products. It exhibits significant low hydrogen, low pH, and high pressure characteristics, significantly different from normal tissues. Hypoxia or ATP accumulation caused by chemoradiotherapy and tumor cell killing promotes the CD39-CD73 adenosine signaling cascade, favoring the proliferation and function of various tumor-promoting cells while negatively impacting tumor suppressor cells (Regateiro, FS, Cobbold, SP & Waldmann, H. Clin. Exp. Immunol. 2013;171:1–7).
[0014] In animal models, the use of antibodies targeting CD73 or genetic knockout of CD73 can effectively block tumor growth and metastasis. Recently, the use of CD73 monoclonal antibodies, small interfering RNA technology, and the specific inhibitor APCP have achieved remarkable therapeutic efficacy in animal studies, providing a new avenue for anti-tumor therapy. Evidence from in vivo studies suggests that targeted blockade of CD73 could be an effective treatment for cancer patients.
[0015] The association between CD73 overexpression and tumor subtypes, prognosis, and patient drug response has suggested that CD73 could serve as an important marker for future personalized tumor treatment and monitoring. Therefore, research on CD73 targets is essential.
[0016] Currently, there is still a need to develop new anti-LAG3 antibody drugs and bispecific antibody drugs that simultaneously target CD73 and LAG3.
[0017] Summary of the Invention
[0018] After in-depth research and creative work, the present inventors have obtained an anti-LAG3-anti-CD73 bispecific antibody. The present inventors surprisingly found that the anti-LAG3-anti-CD73 bispecific antibody of the present invention (also referred to as the antibody or the antibody of the present invention) has good anti-tumor activity. The following invention is provided:
[0019] One aspect of the present invention relates to a bispecific antibody comprising a first protein functional region and a second protein functional region, wherein:
[0020] The first protein functional region targets LAG3,
[0021] The second protein functional region targets a target different from LAG3 (e.g., CD73 or PD-1),
[0022] Wherein, the first protein functional region is an anti-LAG3 antibody or an antigen-binding fragment thereof, wherein the anti-LAG3 antibody comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3, and the light chain variable region comprises LCDR1, LCDR2 and LCDR3, wherein,
[0023] The amino acid sequence of HCDR1 is shown in SEQ ID NO: 9,
[0024] The amino acid sequence of HCDR2 is shown in SEQ ID NO: 10,
[0025] The amino acid sequence of HCDR3 is shown in SEQ ID NO: 11;
[0026] The amino acid sequence of LCDR1 is shown in SEQ ID NO: 12 or SEQ ID NO: 17,
[0027] The amino acid sequence of LCDR2 is shown in SEQ ID NO: 13 or SEQ ID NO: 15,
[0028] The amino acid sequence of LCDR3 is shown in SEQ ID NO: 14 or SEQ ID NO: 16.
[0029] In some embodiments of the present invention, the bispecific antibody, wherein,
[0030] The amino acid sequence of LCDR1 is shown in SEQ ID NO: 12,
[0031] The amino acid sequence of LCDR2 is shown in SEQ ID NO: 13, and
[0032] The amino acid sequence of LCDR3 is shown in SEQ ID NO: 14;
[0033] or
[0034] The amino acid sequence of LCDR1 is shown in SEQ ID NO: 12,
[0035] The amino acid sequence of LCDR2 is shown in SEQ ID NO: 15, and
[0036] The amino acid sequence of LCDR3 is shown in SEQ ID NO: 16;
[0037] or
[0038] The amino acid sequence of LCDR1 is shown in SEQ ID NO: 17,
[0039] The amino acid sequence of LCDR2 is shown in SEQ ID NO: 15, and
[0040] The amino acid sequence of LCDR3 is shown in SEQ ID NO: 14;
[0041] or
[0042] The amino acid sequence of LCDR1 is shown in SEQ ID NO: 12,
[0043] The amino acid sequence of LCDR2 is shown in SEQ ID NO: 13, and
[0044] The amino acid sequence of LCDR3 is shown in SEQ ID NO: 16;
[0045] or
[0046] The amino acid sequence of LCDR1 is shown in SEQ ID NO: 12,
[0047] The amino acid sequence of LCDR2 is shown in SEQ ID NO: 15, and
[0048] The amino acid sequence of LCDR3 is shown in SEQ ID NO: 14;
[0049] or
[0050] The amino acid sequence of LCDR1 is shown in SEQ ID NO: 17,
[0051] The amino acid sequence of LCDR2 is shown in SEQ ID NO: 13, and
[0052] The amino acid sequence of LCDR3 is shown in SEQ ID NO: 14;
[0053] or
[0054] The amino acid sequence of LCDR1 is shown in SEQ ID NO: 17,
[0055] The amino acid sequence of LCDR2 is shown in SEQ ID NO: 13, and
[0056] The amino acid sequence of LCDR3 is shown in SEQ ID NO: 16;
[0057] or
[0058] The amino acid sequence of LCDR1 is shown in SEQ ID NO: 17,
[0059] The amino acid sequence of LCDR2 is shown in SEQ ID NO: 15, and
[0060] The amino acid sequence of LCDR3 is shown in SEQ ID NO:16.
[0061] In some embodiments of the present invention, the bispecific antibody, wherein,
[0062] The amino acid sequence of HCDR1 is shown in SEQ ID NO: 9,
[0063] The amino acid sequence of HCDR2 is shown in SEQ ID NO: 10,
[0064] The amino acid sequence of HCDR3 is shown in SEQ ID NO: 11;
[0065] The amino acid sequence of LCDR1 is shown in SEQ ID NO: 12,
[0066] The amino acid sequence of LCDR2 is shown in SEQ ID NO: 13, and
[0067] The amino acid sequence of LCDR3 is shown in SEQ ID NO:14.
[0068] In some embodiments of the present invention, the bispecific antibody, wherein,
[0069] The amino acid sequence of HCDR1 is shown in SEQ ID NO: 9,
[0070] The amino acid sequence of HCDR2 is shown in SEQ ID NO: 10,
[0071] The amino acid sequence of HCDR3 is shown in SEQ ID NO: 11;
[0072] The amino acid sequence of LCDR1 is shown in SEQ ID NO: 12,
[0073] The amino acid sequence of LCDR2 is shown in SEQ ID NO: 15, and
[0074] The amino acid sequence of LCDR3 is shown in SEQ ID NO:16.
[0075] In some embodiments of the present invention, the bispecific antibody, wherein,
[0076] The amino acid sequence of HCDR1 is shown in SEQ ID NO: 9,
[0077] The amino acid sequence of HCDR2 is shown in SEQ ID NO: 10,
[0078] The amino acid sequence of HCDR3 is shown in SEQ ID NO: 11;
[0079] The amino acid sequence of LCDR1 is shown in SEQ ID NO: 17,
[0080] The amino acid sequence of LCDR2 is shown in SEQ ID NO: 15, and
[0081] The amino acid sequence of LCDR3 is shown in SEQ ID NO:14.
[0082] In some embodiments of the present invention, the bispecific antibody, wherein,
[0083] The amino acid sequence of HCDR1 is shown in SEQ ID NO: 9,
[0084] The amino acid sequence of HCDR2 is shown in SEQ ID NO: 10,
[0085] The amino acid sequence of HCDR3 is shown in SEQ ID NO: 11;
[0086] The amino acid sequence of LCDR1 is shown in SEQ ID NO: 12,
[0087] The amino acid sequence of LCDR2 is shown in SEQ ID NO: 13, and
[0088] The amino acid sequence of LCDR3 is shown in SEQ ID NO:16.
[0089] In some embodiments of the present invention, the bispecific antibody, wherein,
[0090] The amino acid sequence of HCDR1 is shown in SEQ ID NO: 9,
[0091] The amino acid sequence of HCDR2 is shown in SEQ ID NO: 10,
[0092] The amino acid sequence of HCDR3 is shown in SEQ ID NO: 11;
[0093] The amino acid sequence of LCDR1 is shown in SEQ ID NO: 12,
[0094] The amino acid sequence of LCDR2 is shown in SEQ ID NO: 15, and
[0095] The amino acid sequence of LCDR3 is shown in SEQ ID NO:14.
[0096] In some embodiments of the present invention, the bispecific antibody, wherein,
[0097] The amino acid sequence of HCDR1 is shown in SEQ ID NO: 9,
[0098] The amino acid sequence of HCDR2 is shown in SEQ ID NO: 10,
[0099] The amino acid sequence of HCDR3 is shown in SEQ ID NO: 11;
[0100] The amino acid sequence of LCDR1 is shown in SEQ ID NO: 17,
[0101] The amino acid sequence of LCDR2 is shown in SEQ ID NO: 13, and
[0102] The amino acid sequence of LCDR3 is shown in SEQ ID NO:14.
[0103] In some embodiments of the present invention, the bispecific antibody, wherein,
[0104] The amino acid sequence of HCDR1 is shown in SEQ ID NO: 9,
[0105] The amino acid sequence of HCDR2 is shown in SEQ ID NO: 10,
[0106] The amino acid sequence of HCDR3 is shown in SEQ ID NO: 11;
[0107] The amino acid sequence of LCDR1 is shown in SEQ ID NO: 17,
[0108] The amino acid sequence of LCDR2 is shown in SEQ ID NO: 13, and
[0109] The amino acid sequence of LCDR3 is shown in SEQ ID NO:16.
[0110] In some embodiments of the present invention, the bispecific antibody, wherein,
[0111] The amino acid sequence of HCDR1 is shown in SEQ ID NO: 9,
[0112] The amino acid sequence of HCDR2 is shown in SEQ ID NO: 10,
[0113] The amino acid sequence of HCDR3 is shown in SEQ ID NO: 11;
[0114] The amino acid sequence of LCDR1 is shown in SEQ ID NO: 17,
[0115] The amino acid sequence of LCDR2 is shown in SEQ ID NO: 15, and
[0116] The amino acid sequence of LCDR3 is shown in SEQ ID NO:16.
[0117] In some embodiments of the present invention, the bispecific antibody, wherein,
[0118] The anti-LAG3 antibody has a heavy chain variable region selected from the amino acid sequences shown in SEQ ID NO: 2 and SEQ ID NO: 44, and a light chain variable region selected from the amino acid sequences shown in SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, and SEQ ID NO: 45;
[0119] Preferably,
[0120] The amino acid sequence of the heavy chain variable region of the anti-LAG3 antibody is shown in SEQ ID NO: 2, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 4;
[0121] The amino acid sequence of the heavy chain variable region of the anti-LAG3 antibody is shown in SEQ ID NO: 2, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 6;
[0122] The amino acid sequence of the heavy chain variable region of the anti-LAG3 antibody is shown in SEQ ID NO: 2, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 8;
[0123] The amino acid sequence of the heavy chain variable region of the anti-LAG3 antibody is shown in SEQ ID NO: 2, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 45;
[0124] The amino acid sequence of the heavy chain variable region of the anti-LAG3 antibody is shown in SEQ ID NO:44, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO:4;
[0125] The amino acid sequence of the heavy chain variable region of the anti-LAG3 antibody is shown in SEQ ID NO:44, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO:6;
[0126] The anti-LAG3 antibody has a heavy chain variable region amino acid sequence as shown in SEQ ID NO:44, and a light chain variable region amino acid sequence as shown in SEQ ID NO:8; or
[0127] The amino acid sequence of the heavy chain variable region of the anti-LAG3 antibody is shown in SEQ ID NO: 44, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 45.
[0128] In some embodiments of the present invention, the bispecific antibody, wherein the anti-LAG3 antibody or antigen-binding fragment thereof is selected from Fab, Fab', F(ab')2, Fd, Fv, dAb, complementarity determining region fragment, single-chain antibody, humanized antibody or chimeric antibody.
[0129] In some embodiments of the present invention, the bispecific antibody, wherein,
[0130] The anti-LAG3 antibody includes non-CDR regions, and the non-CDR regions are derived from human antibodies.
[0131] In some embodiments of the present invention, the bispecific antibody is an anti-LAG3-anti-CD73 bispecific antibody.
[0132] In some embodiments of the present invention, the bispecific antibody, wherein,
[0133] The second protein functional region is an anti-CD73 antibody or an antigen-binding fragment thereof, wherein the anti-CD73 antibody comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises a HCDR1 with an amino acid sequence as shown in SEQ ID NO: 25, a HCDR2 with an amino acid sequence as shown in SEQ ID NO: 26, and a HCDR3 with an amino acid sequence as shown in SEQ ID NO: 27; and
[0134] The light chain variable region comprises LCDR1 with an amino acid sequence as shown in SEQ ID NO: 28, LCDR2 with an amino acid sequence as shown in SEQ ID NO: 29, and LCDR3 with an amino acid sequence as shown in SEQ ID NO: 30.
[0135] In some embodiments of the present invention, the bispecific antibody, wherein the heavy chain variable region of the anti-CD73 antibody is selected from the amino acid sequences shown in SEQ ID NO: 31, SEQ ID NO: 33, SEQ ID NO: 35, and SEQ ID NO: 46; and the light chain variable region is selected from the amino acid sequences shown in SEQ ID NO: 32, SEQ ID NO: 34, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 47, and SEQ ID NO: 62;
[0136] Preferably,
[0137] The amino acid sequence of the heavy chain variable region of the anti-CD73 antibody is shown in SEQ ID NO: 31, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 32;
[0138] The amino acid sequence of the heavy chain variable region of the anti-CD73 antibody is shown in SEQ ID NO: 31, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 34;
[0139] The amino acid sequence of the heavy chain variable region of the anti-CD73 antibody is shown in SEQ ID NO: 31, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 36;
[0140] The amino acid sequence of the heavy chain variable region of the anti-CD73 antibody is shown in SEQ ID NO: 31, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 37;
[0141] The amino acid sequence of the heavy chain variable region of the anti-CD73 antibody is shown in SEQ ID NO: 31, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 47;
[0142] The amino acid sequence of the heavy chain variable region of the anti-CD73 antibody is shown in SEQ ID NO: 31, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 62;
[0143] The amino acid sequence of the heavy chain variable region of the anti-CD73 antibody is shown in SEQ ID NO: 33, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 32;
[0144] The amino acid sequence of the heavy chain variable region of the anti-CD73 antibody is shown in SEQ ID NO: 33, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 34;
[0145] The amino acid sequence of the heavy chain variable region of the anti-CD73 antibody is shown in SEQ ID NO: 33, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 36;
[0146] The amino acid sequence of the heavy chain variable region of the anti-CD73 antibody is shown in SEQ ID NO: 33, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 37;
[0147] The amino acid sequence of the heavy chain variable region of the anti-CD73 antibody is shown in SEQ ID NO: 33, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 47;
[0148] The amino acid sequence of the heavy chain variable region of the anti-CD73 antibody is shown in SEQ ID NO: 33, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 62;
[0149] The amino acid sequence of the heavy chain variable region of the anti-CD73 antibody is shown in SEQ ID NO: 35, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 32;
[0150] The amino acid sequence of the heavy chain variable region of the anti-CD73 antibody is shown in SEQ ID NO: 35, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 34;
[0151] The amino acid sequence of the heavy chain variable region of the anti-CD73 antibody is shown in SEQ ID NO: 35, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 36;
[0152] The amino acid sequence of the heavy chain variable region of the anti-CD73 antibody is shown in SEQ ID NO: 35, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 37;
[0153] The amino acid sequence of the heavy chain variable region of the anti-CD73 antibody is shown in SEQ ID NO: 35, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 47;
[0154] The amino acid sequence of the heavy chain variable region of the anti-CD73 antibody is shown in SEQ ID NO: 35, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 62;
[0155] The amino acid sequence of the heavy chain variable region of the anti-CD73 antibody is shown in SEQ ID NO: 46, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 32;
[0156] The amino acid sequence of the heavy chain variable region of the anti-CD73 antibody is shown in SEQ ID NO: 46, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 34;
[0157] The amino acid sequence of the heavy chain variable region of the anti-CD73 antibody is shown in SEQ ID NO:46, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO:36;
[0158] The amino acid sequence of the heavy chain variable region of the anti-CD73 antibody is shown in SEQ ID NO: 46, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 37;
[0159] The anti-CD73 antibody has a heavy chain variable region amino acid sequence as shown in SEQ ID NO: 46, and a light chain variable region amino acid sequence as shown in SEQ ID NO: 47; or
[0160] The amino acid sequence of the heavy chain variable region of the anti-CD73 antibody is shown in SEQ ID NO:46, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO:62.
[0161] In some embodiments of the present invention, the bispecific antibody, wherein,
[0162] The anti-LAG3 antibody or the anti-CD73 antibody further comprises a constant region, wherein the constant region is derived from a human antibody;
[0163] Preferably, the constant region of the anti-LAG3 antibody or the anti-CD73 antibody is selected from the constant region of human IgG1, IgG2, IgG3 or IgG4;
[0164] Preferably, the anti-LAG3 antibody comprises a heavy chain constant region and a light chain constant region, the heavy chain constant region is Ig gamma-1 chain C region (e.g., as shown in SEQ ID NO: 18) or Ig gamma-4 chain C region (e.g., as shown in SEQ ID NO: 20); the light chain constant region is Ig kappa chain C region (e.g., as shown in SEQ ID NO: 19);
[0165] Preferably, the anti-CD73 antibody comprises a heavy chain constant region and a light chain constant region, the heavy chain constant region is Ig gamma-1 chain C region (e.g., as shown in SEQ ID NO: 18) or Ig gamma-4 chain C region (e.g., as shown in SEQ ID NO: 20); the light chain constant region is Ig kappa chain C region (e.g., as shown in SEQ ID NO: 19).
[0166] Amino acid sequence of the IgG1 heavy chain constant region
[0167] In some embodiments of the present invention, the bispecific antibody is characterized by any one of the following (1) to (4):
[0168] (1)
[0169] The anti-LAG3 antibody is of human IgG1 subtype,
[0170] Wherein, according to the EU numbering system, the heavy chain constant region of the antibody has the following mutations:
[0171] L234A and L235A,
[0172] L234A and G237A,
[0173] L235A and G237A, or
[0174] L234A, L235A, and G237A;
[0175] (2)
[0176] The anti-LAG3 antibody is of human IgG4 subtype,
[0177] Wherein, according to the EU numbering system, the heavy chain constant region of the antibody has the following mutations:
[0178] F234A and L235A,
[0179] F234A and G237A,
[0180] L235A and G237A, or
[0181] F234A, L235A, and G237A;
[0182] (3)
[0183] The anti-CD73 antibody is of human IgG1 subtype,
[0184] Wherein, according to the EU numbering system, the heavy chain constant region of the antibody has the following mutations:
[0185] L234A and L235A,
[0186] L234A and G237A,
[0187] L235A and G237A, or
[0188] L234A, L235A, and G237A;
[0189] or,
[0190] (4)
[0191] The anti-CD73 antibody is of human IgG4 subtype,
[0192] Wherein, according to the EU numbering system, the heavy chain constant region of the antibody has the following mutations:
[0193] F234A and L235A,
[0194] F234A and G237A,
[0195] L235A and G237A, or
[0196] F234A, L235A and G237A.
[0197] In some embodiments of the present invention, the bispecific antibody, wherein,
[0198] The bispecific antibody is in the IgG-scFv format;
[0199] Preferably, the first protein functional region is an immunoglobulin, and the second protein functional region is a single-chain antibody; or
[0200] Preferably, the first protein functional region is a single-chain antibody, and the second protein functional region is an immunoglobulin targeting a target other than LAG3 (e.g., CD73 or PD-1).
[0201] In some embodiments of the present invention, the bispecific antibody comprises:
[0202] Targeting the first protein domain of LAG3, and
[0203] Targeting the second protein functional domain of CD73;
[0204] in,
[0205] The first protein functional region is an anti-LAG3 antibody, and the anti-LAG3 antibody is an immunoglobulin, and the second protein functional region is an anti-CD73 single-chain antibody; or
[0206] The first protein functional region is an anti-LAG3 single-chain antibody, the second protein functional region is an anti-CD73 antibody, and the anti-CD73 antibody is an immunoglobulin.
[0207] In some embodiments of the present invention, the bispecific antibody, wherein,
[0208] The heavy chain variable region of the immunoglobulin comprises HCDR1-HCDR3 as shown in SEQ ID NOs:9-11, respectively, and the light chain variable region comprises LCDR1-LCDR3 as shown in SEQ ID NOs:12-14, respectively, and the heavy chain variable region of the single-chain antibody comprises HCDR1-HCDR3 as shown in SEQ ID NOs:25-27, respectively, and the light chain variable region comprises LCDR1-LCDR3 as shown in SEQ ID NOs:28-30, respectively; or
[0209] The heavy chain variable region of the single-chain antibody comprises HCDR1-HCDR3 as shown in SEQ ID NOs:9-11, respectively, and the light chain variable region comprises LCDR1-LCDR3 as shown in SEQ ID NOs:12-14, respectively, and the heavy chain variable region of the immunoglobulin comprises HCDR1-HCDR3 as shown in SEQ ID NOs:25-27, respectively, and the light chain variable region comprises LCDR1-LCDR3 as shown in SEQ ID NOs:28-30, respectively.
[0210] In some embodiments of the present invention, the bispecific antibody, wherein,
[0211] The heavy chain variable region of the immunoglobulin is selected from the amino acid sequences shown in SEQ ID NO: 2 and SEQ ID NO: 44, and the light chain variable region is selected from the amino acid sequences shown in SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8 and SEQ ID NO: 45, and the heavy chain variable region of the single-chain antibody is selected from the amino acid sequences shown in SEQ ID NO: 31, SEQ ID NO: 33, SEQ ID NO: 35 and SEQ ID NO: 46; the light chain variable region is selected from the amino acid sequences shown in SEQ ID NO: 32, SEQ ID NO: 34, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 47 and SEQ ID NO: 62; or
[0212] The heavy chain variable region of the single-chain antibody is selected from the amino acid sequences shown in SEQ ID NO: 2 and SEQ ID NO: 44, and the light chain variable region is selected from the amino acid sequences shown in SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8 and SEQ ID NO: 45, and the heavy chain variable region of the immunoglobulin is selected from the amino acid sequences shown in SEQ ID NO: 31, SEQ ID NO: 33, SEQ ID NO: 35 and SEQ ID NO: 46; the light chain variable region is selected from the amino acid sequences shown in SEQ ID NO: 32, SEQ ID NO: 34, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 47 and SEQ ID NO: 62.
[0213] In some embodiments of the present invention, the bispecific antibody is selected from any one of the following (1)-(24):
[0214] (1)
[0215] The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 2, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 4; and the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 31, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 32;
[0216] (2)
[0217] The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 2, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 4; and the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 33, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 34;
[0218] (3)
[0219] The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 2, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 4; and the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 35, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 36;
[0220] (4)
[0221] The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 2, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 4; and the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 35, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 37;
[0222] (5)
[0223] The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 2, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 4; and the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 46, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 47;
[0224] (6)
[0225] The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 2, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 4; and the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 35, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 62;
[0226] (7)
[0227] The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 44, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 45; and the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 31, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 32;
[0228] (8)
[0229] The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 44, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 45; and the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 33, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 34;
[0230] (9)
[0231] The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO:44, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO:45; and the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO:35, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO:36;
[0232] (10)
[0233] The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 44, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 45; and the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 35, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 37;
[0234] (11)
[0235] The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 44, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 45; and the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 46, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 47;
[0236] (12)
[0237] The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 44, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 45; and the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 35, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 62;
[0238] (13)
[0239] The amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 2, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 4; and the amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 31, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 32;
[0240] (14)
[0241] The amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 2, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 4; and the amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 33, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 34;
[0242] (15)
[0243] The amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 2, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 4; and the amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 35, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 36;
[0244] (16)
[0245] The amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 2, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 4; and the amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 35, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 37;
[0246] (17)
[0247] The amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 2, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 4; and the amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 46, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 47;
[0248] (18)
[0249] The amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 2, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 4; and the amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 35, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 62;
[0250] (19)
[0251] The amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 44, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 45; and the amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 31, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 32;
[0252] (20)
[0253] The amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 44, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 45; and the amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 33, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 34;
[0254] (twenty one)
[0255] The amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 44, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 45; and the amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 35, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 36;
[0256] (twenty two)
[0257] The amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 44, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 45; and the amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 35, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 37;
[0258] (twenty three)
[0259] The amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 44, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 45; and, the amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 46, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 47; and
[0260] (twenty four)
[0261] The amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO:44, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO:45; and the amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO:35, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO:62.
[0262] In some embodiments of the present invention, the bispecific antibody, wherein the immunoglobulin is of human IgG1 subtype, and according to the EU numbering system, the heavy chain constant region of the immunoglobulin has the following mutations:
[0263] L234A and L235A;
[0264] L234A and G237A;
[0265] L235A and G237A;
[0266] or
[0267] L234A, L235A and G237A.
[0268] In the present invention, unless otherwise specified, the letters before the site represent the amino acid before mutation, and the letters after the site represent the amino acid after mutation.
[0269] In some embodiments of the present invention, according to the EU numbering system, the heavy chain constant region of the immunoglobulin further has one or more mutations selected from the following:
[0270] N297A, D265A, D270A, P238D, L328E, E233D, H268D, P271G, A330R, C226S, C229S, E233P, P331S, S267E, L328F, A330L, M252Y, S254T, T256E, N297Q, P238S, P238A, A327Q, A327G, P329A, K322A, T394D, G236R, G236A, L328R, A330S, P331S, H268A, E318A, and K320A.
[0271] In some embodiments of the present invention, the bispecific antibody, wherein the immunoglobulin is of human IgG4 subtype, and according to the EU numbering system, the heavy chain constant region of the immunoglobulin has the following mutations:
[0272] F234A and L235A,
[0273] F234A and G237A,
[0274] L235A and G237A, or
[0275] F234A, L235A and G237A.
[0276] In some embodiments of the present invention, the bispecific antibody, wherein the first protein functional region and the second protein functional region are independently 1, 2 or more;
[0277] Preferably, the first protein functional region and the second protein functional region are directly connected or connected through a linker;
[0278] Preferably, the heavy chain variable region and the light chain variable region of the anti-LAG3 single-chain antibody are directly connected or connected through a linker;
[0279] Preferably, the heavy chain variable region and the light chain variable region of the anti-CD73 single-chain antibody are directly connected or connected through a linker;
[0280] Preferably, the linker is independently a polypeptide represented by SEQ ID NO: 48 (GGGGS), or a polypeptide composed of multiple (e.g., 2, 3, 4, 5 or 6) polypeptides represented by SEQ ID NO: 48 connected in series;
[0281] Preferably, the linker is independently a polypeptide having one or more glycine residues connected to the C-terminus of the polypeptide shown in SEQ ID NO: 48 or a polypeptide composed of multiple (eg, 2, 3, 4, 5 or 6) polypeptides shown in SEQ ID NO: 46 connected in series.
[0282] In some embodiments of the present invention, in the bispecific antibody, each single-chain antibody is respectively linked to the C-terminus or N-terminus of two heavy chains of an immunoglobulin.
[0283] In some embodiments of the present invention, the bispecific antibody comprises:
[0284] Targeting the first protein domain of LAG3, and
[0285] Targeting the second protein functional domain of CD73;
[0286] The number of the first protein functional region is one, and the number of the second protein functional region is two;
[0287] Wherein, the first protein functional region is an immunoglobulin, and the second protein functional region is a single-chain antibody;
[0288] The amino acid sequence of the heavy chain of the immunoglobulin is shown in SEQ ID NO: 38, and the amino acid sequence of the light chain thereof is shown in SEQ ID NO: 39;
[0289] The amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 35, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 62; or, the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 46, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 47;
[0290] Each single-chain antibody is linked to the C-terminus of two heavy chains of an immunoglobulin;
[0291] The first protein functional region and the second protein functional region are connected by a first linker; and the heavy chain variable region of the single-chain antibody and the light chain variable region of the single-chain antibody are connected by a second linker; the first linker and the second linker are the same or different;
[0292] Preferably, the amino acid sequences of the first linker and the second linker are independently selected from SEQ ID NO: 42 and SEQ ID NO: 43;
[0293] Preferably, the amino acid sequences of the first linker and the second linker are both as shown in SEQ ID NO: 43;
[0294] Preferably, according to the EU numbering system, the constant region of the heavy chain of the immunoglobulin (SEQ ID NO: 38) comprises the following mutations:
[0295] L234A and L235A,
[0296] L234A and G237A,
[0297] L235A and G237A, or
[0298] L234A, L235A and G237A.
[0299] In some embodiments of the present invention, the bispecific antibody comprises:
[0300] Targeting the first protein domain of LAG3, and
[0301] Targeting the second protein functional domain of CD73;
[0302] The number of the first protein functional regions is 2, and the number of the second protein functional region is 1;
[0303] Wherein, the first protein functional region is a single-chain antibody, and the second protein functional region is an immunoglobulin;
[0304] The amino acid sequence of the heavy chain of the immunoglobulin is shown in SEQ ID NO: 40, and the amino acid sequence of the light chain thereof is shown in SEQ ID NO: 41;
[0305] The amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 2, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 4; or the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 44, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 45;
[0306] Each single-chain antibody is linked to the C-terminus of two heavy chains of an immunoglobulin;
[0307] The first protein functional region and the second protein functional region are connected by a first linker; and the heavy chain variable region of the single-chain antibody and the light chain variable region of the single-chain antibody are connected by a second linker; the first linker and the second linker are the same or different;
[0308] Preferably, the amino acid sequences of the first linker and the second linker are independently selected from SEQ ID NO: 42 and SEQ ID NO: 43;
[0309] Preferably, the amino acid sequences of the first linker and the second linker are both as shown in SEQ ID NO: 43;
[0310] Preferably, according to the EU numbering system, the constant region of the heavy chain of the immunoglobulin (SEQ ID NO: 40) comprises the following mutations:
[0311] L234A and L235A,
[0312] L234A and G237A,
[0313] L235A and G237A, or
[0314] L234A, L235A and G237A.
[0315] The bispecific antibody according to any one of the present invention is used for treating or preventing tumors;
[0316] Preferably, the tumor is one or more selected from ovarian cancer, esophageal cancer, melanoma, hematological tumor, glioblastoma, renal cell carcinoma, lung cancer, prostate cancer, bladder cancer, colon cancer, rectal cancer, liver cancer, gastric cancer, breast cancer, brain cancer, pancreatic cancer, thyroid cancer, head and neck cancer, and kidney cancer;
[0317] Preferably, the lung cancer is non-small cell lung cancer;
[0318] Preferably, the blood tumor is leukemia;
[0319] Preferably, the esophageal cancer is esophageal squamous cell carcinoma.
[0320] Another aspect of the present invention relates to an isolated nucleic acid molecule encoding the bispecific antibody of any one of the present invention.
[0321] Yet another aspect of the present invention relates to a recombinant vector comprising the isolated nucleic acid molecule of the present invention.
[0322] Another aspect of the present invention relates to a host cell comprising the isolated nucleic acid molecule of the present invention, or comprising the recombinant vector of the present invention.
[0323] Another aspect of the present invention relates to a method for preparing the bispecific antibody according to any one of the present invention, comprising the steps of culturing the host cell of the present invention under suitable conditions, and recovering the bispecific antibody from the cell culture.
[0324] Another aspect of the present invention relates to a pharmaceutical composition comprising the bispecific antibody according to any one of the present invention; optionally, it further comprises a pharmaceutically acceptable excipient.
[0325] Another aspect of the present invention relates to use of the bispecific antibody described in any one of the present invention in the preparation of a medicament for treating or preventing tumors;
[0326] Preferably, the tumor is one or more selected from ovarian cancer, esophageal cancer, melanoma, hematological tumor, glioblastoma, renal cell carcinoma, lung cancer, prostate cancer, bladder cancer, colon cancer, rectal cancer, liver cancer, gastric cancer, breast cancer, brain cancer, pancreatic cancer, thyroid cancer, head and neck cancer, and kidney cancer;
[0327] Preferably, the lung cancer is non-small cell lung cancer;
[0328] Preferably, the blood tumor is leukemia;
[0329] Preferably, the esophageal cancer is esophageal squamous cell carcinoma.
[0330] Another aspect of the present invention relates to a method for treating or preventing tumors, comprising the step of administering an effective amount of the bispecific antibody according to any one of the present invention to a subject in need thereof;
[0331] Preferably, the tumor is one or more selected from ovarian cancer, esophageal cancer, melanoma, hematological tumor, glioblastoma, renal cell carcinoma, lung cancer, prostate cancer, bladder cancer, colon cancer, rectal cancer, liver cancer, gastric cancer, breast cancer, brain cancer, pancreatic cancer, thyroid cancer, head and neck cancer, and kidney cancer;
[0332] Preferably, the lung cancer is non-small cell lung cancer;
[0333] Preferably, the blood tumor is leukemia;
[0334] Preferably, the esophageal cancer is esophageal squamous cell carcinoma.
[0335] In one or more embodiments of the present invention, the method for treating or preventing tumors, wherein:
[0336] The single administration dose of the anti-LAG3-anti-CD73 bispecific antibody is 0.1-100 mg per kg body weight, preferably 1-15 mg, 1-12 mg, 1-10 mg (e.g., 1 mg, 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg or 10 mg) or 6-10 mg; alternatively, the single administration dose of the anti-LAG3-anti-CD73 bispecific antibody is 10-1000 mg per subject (e.g., about 100 mg, about 150 mg, about 200 mg, about 250 mg, about 300 mg, about 350 mg, about 400 mg, about 450 mg, about 500 mg, about 600 mg, about 700 mg, about 800 mg, about 900 mg or about 1000 mg), preferably 50-500 mg, 100-400 mg, 150-300 mg, 150-250 mg or 200 mg;
[0337] Preferably, the drug is administered once every 3 days, 4 days, 5 days, 6 days, 10 days, 1 week, 2 weeks or 3 weeks;
[0338] Preferably, the administration is by intravenous drip or intravenous injection.
[0339] In some embodiments, the anti-LAG3-anti-CD73 bispecific antibody is administered in a cycle of 2 weeks (14 days) or 3 weeks (21 days), and the anti-LAG3-anti-CD73 bispecific antibody is preferably administered intravenously on the first day (D1) of each cycle. For example, the anti-LAG3-anti-CD73 bispecific antibody is administered once every two weeks (q2w) or once every three weeks (q3w).
[0340] However, it should be recognized that the total daily dose of the medicament (e.g., pharmaceutical composition) or pharmaceutical active ingredient (e.g., anti-LAG3-anti-CD73 bispecific antibody) of the present invention must be determined by the attending physician within the scope of sound medical judgment. For any particular patient, the specific therapeutically effective dosage level must be determined based on a variety of factors, including the specific tumor type and severity being treated; the specific pharmaceutical formulation used; the patient's age, weight, general health, sex, and diet; the time of administration, route of administration, and excretion rate; the duration of treatment; other drugs used concomitantly; and similar factors well known in the medical field. For example, it is common practice in the art to start administering a dose lower than that required to achieve the desired therapeutic effect and gradually increase the dose until the desired effect is achieved.
[0341] Unless otherwise indicated, scientific and technical terms used herein have the meanings commonly understood by those skilled in the art. Furthermore, the laboratory procedures for cell culture, molecular genetics, nucleic acid chemistry, and immunology used herein are conventional procedures widely used in the relevant fields. To facilitate a better understanding of the present invention, definitions and explanations of relevant terms are provided below.
[0342] As used herein, the term EC 50 It refers to the concentration for 50% of maximal effect, which is the concentration that can cause 50% of the maximum effect.
[0343] As used herein, the term "antibody" refers to an immunoglobulin molecule typically composed of two pairs of polypeptide chains, each pair having one "light" (L) chain and one "heavy" (H) chain. Antibody light chains can be classified as kappa and lambda light chains. Heavy chains can be classified as μ, δ, γ, α, or ε, and define the antibody's isotype as IgM, IgD, IgG, IgA, and IgE, respectively. Within the light and heavy chains, the variable and constant regions are connected by a "J" region of about 12 or more amino acids, and the heavy chain also contains a "D" region of about 3 or more amino acids. Each heavy chain consists of a heavy chain variable region (VH) and a heavy chain constant region (CH). The heavy chain constant region consists of three domains (CH1, CH2, and CH3). Each light chain consists of a light chain variable region (VL) and a light chain constant region (CL). The light chain constant region consists of one domain, CL. The constant region of an antibody can mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (C1q) of the classical complement system. The VH and VL regions can also be further subdivided into regions of high variability, called complementarity determining regions (CDRs), interspersed with more conserved regions called framework regions (FRs). Each VH and VL consists of three CDRs and four FRs arranged from the amino terminus to the carboxyl terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4. The variable regions (VH and VL) of each heavy chain / light chain pair form the antibody binding site. The assignment of amino acids to regions or domains follows Bethesda Md, Kabat Sequences of Proteins of Immunological Interest (National Institutes of Health, (1987 and 1991)), or Chothia & Lesk J. Mol. Biol. 1987; 196: 901-917; Chothia et al. Nature 1989; 342: 878-883, or the IMGT numbering system as defined by Ehrenmann F, Kaas Q, Lefranc MP. IMGT / 3Dstructure-DB and IMGT / DomainGapAlign: a database and a tool for immunoglobulins or antibodies, T cell receptors, MHC, IgSF and MhcSF[J]. Nucleic acids research, 2009; 38(suppl_1): D301-D307.
[0344] The term "antibody" is not limited to any particular method of producing the antibody. For example, it includes recombinant antibodies, monoclonal antibodies, and polyclonal antibodies. The antibody can be of different isotypes, for example, IgG (e.g., IgG1, IgG2, IgG3, or IgG4 subtypes), IgA1, IgA2, IgD, IgE, or IgM antibodies.
[0345] As used herein, the terms "monoclonal antibody" and "monoclonal antibody" refer to an antibody or an antibody fragment from a group of highly homologous antibody molecules, that is, a group of identical antibody molecules except for possible spontaneous natural mutations. Monoclonal antibodies have high specificity for a single epitope on an antigen. Polyclonal antibodies are relative to monoclonal antibodies and usually contain at least two or more different antibodies, and these different antibodies usually recognize different epitopes on the antigen. Monoclonal antibodies can usually be obtained using the hybridoma technology first reported by Kohler et al. ( G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity [J]. Nature, 1975; 256 (5517): 495), but it can also be obtained by using recombinant DNA technology (see, for example, US Patent 4,816,567).
[0346] As used herein, the term "humanized antibody" refers to an antibody or antibody fragment obtained by replacing all or part of the CDR region of a human immunoglobulin (recipient antibody) with the CDR region of a non-human antibody (donor antibody), wherein the donor antibody can be a non-human (e.g., mouse, rat, or rabbit) antibody with the desired specificity, affinity, or reactivity. In addition, some amino acid residues in the framework region (FR) of the recipient antibody can also be replaced with amino acid residues of the corresponding non-human antibody, or with amino acid residues of other antibodies, to further improve or optimize the performance of the antibody. For more details on humanized antibodies, see, for example, Jones et al., Nature 1986; 321: 522 525; Reichmann et al., Nature, 1988; 332: 323 329; Presta, Curr. Op. Struct. Biol. 1992; 2: 593-596; and Clark, Immunol. Today 2000; 21: 397 402.
[0347] As used herein, the term "isolated" or "isolated" refers to something that is obtained artificially from its natural state. If a substance or component is "isolated" in nature, it may be that its natural environment has been changed, or that the substance has been separated from its natural environment, or both. For example, a certain unisolated polynucleotide or polypeptide naturally exists in a living animal, and a highly pure identical polynucleotide or polypeptide isolated from this natural state is called isolated. The term "isolated" or "isolated" does not exclude the presence of artificial or synthetic substances, nor does it exclude the presence of other impure substances that do not affect the activity of the substance.
[0348] As used herein, the term "vector" refers to a nucleic acid delivery vehicle into which a polynucleotide can be inserted. When a vector is capable of expressing a protein encoded by the inserted polynucleotide, it is referred to as an expression vector. A vector can be introduced into a host cell via transformation, transduction, or transfection, allowing the genetic material it carries to be expressed in the host cell. Vectors are well known to those skilled in the art and include, but are not limited to, plasmids; phagemids; cosmids; artificial chromosomes, such as yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs), or P1-derived artificial chromosomes (PACs); bacteriophages, such as lambda phage or M13 phage, and animal viruses. Animal viruses that can be used as vectors include, but are not limited to, retroviruses (including lentiviruses), adenoviruses, adeno-associated viruses, herpes viruses (such as herpes simplex virus), poxviruses, baculoviruses, papillomaviruses, and papillomas (such as SV40). A vector can contain a variety of elements that control expression, including, but not limited to, promoter sequences, transcription initiation sequences, enhancer sequences, selection elements, and reporter genes. Additionally, a vector may contain an origin of replication.
[0349] As used herein, the term "host cell" refers to a cell that can be used to introduce a vector, including but not limited to prokaryotic cells such as Escherichia coli or Bacillus subtilis, fungal cells such as yeast cells or Aspergillus, insect cells such as S2 Drosophila cells or Sf9, or animal cells such as fibroblasts, CHO cells, GS cells, COS cells, NSO cells, HeLa cells, BHK cells, HEK 293 cells or human cells.
[0350] As used herein, the term "specific binding" refers to a non-random binding reaction between two molecules, such as an antibody and its antigen. In certain embodiments, an antibody that specifically binds to an antigen (or has specificity for an antigen) means that the antibody binds to the antigen with a specificity of less than about 10 -5 M, for example, less than about 10 -6 M, 10 -7 M, 10-8 M, 10 -9 M or 10 -10 Affinity of M or less (K D ) binds to the antigen.
[0351] As used herein, the term "K D " refers to the dissociation equilibrium constant of a specific antibody-antigen interaction, which is used to describe the binding affinity between the antibody and the antigen. The smaller the equilibrium dissociation constant, the tighter the antibody-antigen binding and the higher the affinity between the antibody and the antigen. Generally, antibodies bind with a dissociation equilibrium constant of less than about 10 -5 M, for example, less than about 10 -6 M, 10 -7 M, 10 -8 M, 10 -9 M or 10 -10 M or less dissociation equilibrium constant (K D ) binds to an antigen (e.g., PD-1 protein). K can be determined using methods known to those skilled in the art. D , for example, using the Fortebio molecular interaction instrument.
[0352] As used herein, the terms "monoclonal antibody" and "monoclonal antibody" have the same meaning and are used interchangeably; the terms "polyclonal antibody" and "polyclonal antibody" have the same meaning and are used interchangeably. In the present invention, amino acids are generally represented by single-letter and three-letter abbreviations known in the art. For example, alanine can be represented by A or Ala.
[0353] As used herein, the term "pharmaceutically acceptable excipient" refers to a carrier and / or excipient that is pharmacologically and / or physiologically compatible with the subject and the active ingredient, which is well known in the art (see, for example, Remington's Pharmaceutical Sciences. Edited by Gennaro AR, 19th ed. Pennsylvania: Mack Publishing Company, 1995), and includes, but is not limited to, pH adjusters, surfactants, adjuvants, and ionic strength enhancers. For example, pH adjusters include, but are not limited to, phosphate buffers; surfactants include, but are not limited to, cationic, anionic, or nonionic surfactants, such as Tween-80; and ionic strength enhancers include, but are not limited to, sodium chloride.
[0354] As used herein, the term "effective amount" refers to an amount sufficient to obtain or at least partially obtain the desired effect. For example, an effective amount for preventing a disease (e.g., a tumor) refers to an amount sufficient to prevent, stop, or delay the occurrence of a disease (e.g., a tumor); an effective amount for treating a disease refers to an amount sufficient to cure or at least partially stop the disease and its complications in a patient already suffering from the disease. Determining such an effective amount is well within the capabilities of those skilled in the art. For example, an amount effective for therapeutic use will depend on the severity of the disease to be treated, the overall state of the patient's own immune system, the patient's general condition such as age, weight, and sex, the mode of administration of the drug, and other treatments administered simultaneously, etc.
[0355] As used herein, reference to the amino acid sequence of lymphocyte-activation gene 3 (LAG3) includes the full-length LAG3 protein, the extracellular fragment of LAG3, or fragments comprising the LAG3 ECD. Reference also includes fusion proteins of the full-length LAG3 protein or the LAG3 ECD, such as fragments fused to the Fc protein fragment of mouse or human IgG (mFc or hFc). However, those skilled in the art understand that mutations or variations (including but not limited to substitutions, deletions, and / or additions) can occur naturally or be artificially introduced into the amino acid sequence of the LAG3 protein without affecting its biological function. Therefore, in the present invention, the terms "LAG3" or "LAG3 protein" include all such sequences, including natural or artificial variants thereof. Furthermore, when describing a sequence fragment of the LAG3 protein, it also includes the corresponding sequence fragments in natural or artificial variants thereof.
[0356] As used herein, when referring to the amino acid sequence of CD73, it includes the full length of the CD73 protein, or the extracellular fragment CD73 ECD of CD73 or a fragment containing CD73 ECD; it also includes a fusion protein of the full length of the CD73 protein or a fusion protein of CD73 ECD, such as a fragment fused with the Fc protein fragment (mFc or hFc) of mouse or human IgG. However, it is understood by those skilled in the art that mutations or variations (including but not limited to substitutions, deletions and / or additions) can be naturally or artificially introduced into the amino acid sequence of the CD73 protein without affecting its biological function. Therefore, in the present invention, the term "CD73" or "CD73 protein" should include all such sequences, including natural or artificial variants thereof. In addition, when describing a sequence fragment of the CD73 protein, it also includes the corresponding sequence fragments in its natural or artificial variants.
[0357] In the present invention, unless otherwise specified, the "first" (e.g., the first protein functional region or the first linker) and "second" (e.g., the second protein functional region or the second linker) are for the purpose of distinguishing references or clarifying expressions, and do not have a typical order meaning.
[0358] Advantageous Effects of the Invention
[0359] The present invention achieves one or more of the following technical effects:
[0360] (1) The bispecific antibody of the present invention can bind specifically to LAG3 and effectively block the binding of LAG3 to MHC-II, thereby specifically relieving the immune suppression of LAG3;
[0361] (2) The bispecific antibody of the present invention can effectively inhibit the enzymatic activity of CD73;
[0362] (3) The bispecific antibody of the present invention can promote T cells to secrete INF-γ;
[0363] (4) There is a synergistic effect between the first protein functional domain and the second protein functional domain in the bispecific antibody of the present invention.
[0364] (5) The bispecific antibody of the present invention can effectively inhibit tumor growth in a mouse transplant tumor model;
[0365] (6) The antibodies of the present invention can effectively treat or prevent tumors. BRIEF DESCRIPTION OF THE DRAWINGS
[0366] Figure 1: ELISA method was used to determine the binding activity of H9L8 (hG4WT), H9L9 (hG4WT), and H9L10 (hG4WT) to the antigen human LAG3-mG1Fc.
[0367] Figure 2: FACS detection of the binding activity of H9L8 (hG4WT), H9L9 (hG4WT), and H9L10 (hG4WT) to the human LAG3 antigen on the surface of 293T-LAG3 cells.
[0368] Figure 3: Competitive flow cytometry analysis of the binding of H9L8 (hG4WT), H9L9 (hG4WT), and H9L10 (hG4WT) to the Raji cell membrane surface antigen MHC II for human LAG3-mG1Fc.
[0369] Figure 4: Mixed lymphocyte reaction (MLR) assay results for the biological activity of anti-LAG3 antibodies in promoting IFN-γ secretion.
[0370] Figure 5: Mixed lymphocyte reaction (MLR) assay results for the biological activity of anti-LAG3 antibodies in promoting IL-2 secretion.
[0371] Figure 6: Biological activity test results of anti-LAG3 antibodies blocking the interaction between LAG3 and MHC-II.
[0372] Figure 7: ELISA determination of the binding of LA5EV1, LA5EV2 and antigen NT5E-His.
[0373] Figure 8: ELISA determination of the binding of NTLAV2, NTLAV7 and antigen NT5E-His.
[0374] FIG9 : ELISA assay for the binding of NTLAV8 to the antigen NT5E-His.
[0375] Figure 10: ELISA determination of the binding of LA5EV1, LA5EV2 and antigen huLAG3-mG1Fc.
[0376] FIG11 : ELISA assay for the binding of NTLAV2, NTLAV7 and antigen huLAG3-mG1Fc.
[0377] Figure 12: ELISA determination of the binding between NTLAV8 and antigen huLAG3-mG1Fc
[0378] FIG13 : Determination of affinity constants between antibody LA5EV1 and hNT5E(1-552)-His.
[0379] FIG14 : Determination of affinity constants between antibody LA5EV2 and hNT5E(1-552)-His.
[0380] FIG15 : Determination of affinity constants between antibody NTLAV2 and hNT5E(1-552)-His.
[0381] FIG16 : Determination of affinity constants between antibody NTLAV7 and hNT5E(1-552)-His.
[0382] FIG17 : Determination of affinity constants of antibody NTLAV8 and hNT5E(1-552)-His.
[0383] FIG18 : Determination of affinity constants between antibody 19F3H2L3 (hG1DM) and hNT5E(1-552)-His.
[0384] FIG19 : Determination of affinity constants of antibody LA5EV1 and huLAG3-mG1Fc.
[0385] FIG20 : Determination of affinity constants of antibody LA5EV2 and huLAG3-mG1Fc.
[0386] FIG21 : Determination of affinity constants of antibody NTLAV2 and huLAG3-mG1Fc.
[0387] FIG22 : Determination of affinity constants of antibody NTLAV7 and huLAG3-mG1Fc.
[0388] FIG23 : Determination of affinity constants of antibody NTLAV8 and huLAG3-mG1Fc.
[0389] FIG24 : Determination of affinity constants between antibody H9L8 (hG4WT) and huLAG3-mG1Fc.
[0390] FIG25 : Determination of affinity constants between antibody Relatlimab and huLAG3-mG1Fc.
[0391] Figure 26: FACS detection of the binding activity of NTLAV8, LA5EV2, H9L8 (hG4WT), and Relatlimab to LAG3 on the surface of 293T-LAG3 cells.
[0392] Figure 27: FACS detection of the binding activity of NTLAV8, LA5EV2, 19F3H2L3 (hG1DM), and CPI-006 to CD73 on the surface of U87-MG cells.
[0393] Figure 28: FACS detection of the competitive binding of NTLAV8, LA5EV2, Relatlimab, H9L8 to MHC II on the surface of Raji cells for human LAG3-mG1Fc antigen.
[0394] FIG29 : Antibodies NTLAV8 and H9L8 (hG4WT) block the interaction between LAG3 and MHCII.
[0395] Figure 30: Detection of anti-CD73-anti-LAG3 bispecific antibodies inhibiting CD73 enzyme activity on the cell membrane surface.
[0396] Figure 31: Mixed lymphocyte reaction assay to detect the biological activity of anti-CD73-anti-LAG3 bispecific antibody in promoting IFN-γ secretion.
[0397] Figure 32: Detection of phagocytic activity potentially mediated by anti-CD73-anti-LAG3 bispecific antibodies on CHO-K1-LAG3-CD73 target cells.
[0398] Figure 33: Pharmacodynamic evaluation of anti-CD73-anti-LAG3 bispecific antibody in a mouse tumor cell subcutaneous transplantation model.
[0399] Figure 34: Effect of anti-CD73-anti-LAG3 bispecific antibody on body weight in a mouse subcutaneous tumor cell transplantation model. DETAILED DESCRIPTION
[0400] The embodiments of the present invention will be described in detail below with reference to the examples. Those skilled in the art will appreciate that the following examples are only intended to illustrate the present invention and should not be construed as limiting the scope of the present invention. Specific techniques or conditions not specified in the examples are based on the techniques or conditions described in the literature in this area (e.g., with reference to "Molecular Cloning Experiment Guide" by J. Sambrook et al., translated by Huang Peitang et al., 3rd edition, Science Press) or product specifications. Reagents or instruments not specified by manufacturer are conventional products that can be purchased commercially.
[0401] The positive control antibody, Relatlimab, has a sequence referenced in U.S. Patent Publication No. US20160326248A1. The heavy chain amino acid sequence is referenced in SEQ ID NO: 1, and the light chain amino acid sequence is referenced in SEQ ID NO: 2. Relatlimab is an anti-LAG3 antibody.
[0402] Relatlimab heavy chain amino acid sequence:
[0403] Relatlimab light chain amino acid sequence:
[0404] Antibody 14C12H1L1 (hG1TM) is an anti-PD-1 antibody produced by Kangfang Biopharmaceuticals.
[0405] Heavy chain amino acid sequence of 14C12H1L1 (hG1TM):
[0406] The amino acid sequence of the light chain of 14C12H1L1 (hG1TM):
[0407] Amino acid sequence of human LAG3-mG1Fc:
[0408] Amino acid sequence of hNT5E(1-552)-His:
[0409] The 293T-LAG3 cell line was constructed by Zhongshan Kangfang Biopharmaceutical Co., Ltd. The 293T-LAG3 cell line was generated by infecting HEK293T cells with a virus. The virus was prepared using a 3rd Generation Lentiviral System, see, for example, A Third Generation Lentivirus Vector with a Conditional Packaging System. Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D, and Naldini LJ Virol. 1998. 72(11):8463-8471. The lentiviral expression vector used was plenti6.3 / V5-huLAG3FL-BSD (LAG3, Genebank ID: NP_002277.4; vector plenti6.3 / V5-BSD, purchased from Invitrogen, product number: K5315-20).
[0410] The Raji-PDL1 cell line was constructed by Zhongshan Kangfang Biopharmaceutical Co., Ltd. The Raji-PDL1 cell line was generated by infecting Raji cells with a virus. The virus was prepared using a 3rd Generation Lentiviral System, see, for example, A Third Generation Lentivirus Vector with a Conditional Packaging System. Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D, and Naldini LJ Virol. 1998. 72(11): 8463-8471. The lentiviral expression vector used was plenti6.3 / V5-PDL1 (PDL1, Genebank ID: NP_054862.1; vector plenti6.3 / V5, purchased from Invitrogen, Cat. No. K5315-20).
[0411] The Jurkat-NFAT-PD1-LAG3 cell line was constructed by Zhongshan Kangfang Biopharmaceutical Co., Ltd. The Jurkat-NFAT-PD1-LAG3 cell line was prepared by virus infection of PD-1 effector cells (PD-1 Effector cells (CPM), manufacturer: Promega, product number: J112A). The virus was prepared using 3rd Generation Lentiviral Systems, see, for example, A Third Generation Lentivirus Vector with a Conditional Packaging System. Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D, and Naldini LJ Virol. 1998. 72(11): 8463-8471. The lentiviral expression vector used was pCDH-huLAG3FL-RFP-NEO (LAG3, Genebank ID: NP_002277.4; vector pCDH-CMV-MCS-EF1-RFP+Neo, purchased from Ubao Bio, product number: VT9005).
[0412] The CHO-K1-LAG3-CD73 cell line was constructed by Zhongshan Kangfang Biopharmaceutical Co., Ltd. The CHO-K1-LAG3-CD73 cell line was prepared by viral infection of CHO-K1 cells (manufacturer: Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, catalog number: 3111C0001CCC000004). The virus was prepared using 3rd Generation Lentiviral Systems, see, for example, A Third Generation Lentivirus Vector with a Conditional Packaging System. Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D, and Naldini LJ Virol. 1998. 72(11): 8463-8471. The lentiviral expression vector used was plenti6.3 / V5-huLAG3FL-BSD (LAG3, Genebank ID: NP_002277.4; vector plenti6.3 / V5-BSD, purchased from Invitrogen, product number: K5315-20) and pCDH-GFP-NT5EFL-puro (NT5E, Genebank ID: NP_002517.1; vector pCDH-puro, purchased from Youbao Biotechnology).
[0413] Sequence information of positive control antibody MEDI9447. MEDI9447 is an anti-CD73 antibody.
[0414] MEDI9447 heavy chain amino acid sequence
[0415] MEDI9447 light chain amino acid sequence
[0416] Sequence information of positive control antibody CPI-006. CPI-006 is an anti-CD73 antibody.
[0417] CPI-006 heavy chain amino acid sequence
[0418] CPI-006 light chain amino acid sequence
[0419] Preparation Example 1: Design and Preparation of Anti-LAG3 Antibodies
[0420] 1. Antibody Design
[0421] Based on the existing LAG3 protein sequence (NCBI Reference Sequence: NP_002277.4) and its three-dimensional crystal structure, the inventors creatively designed a series of antibody sequences. Through extensive screening and testing, they ultimately obtained humanized monoclonal antibodies that specifically bind to LAG3, designated H9L8, H9L9, and H9L10. The amino acid sequences and coding sequences of the heavy and light chain variable regions of these monoclonal antibodies are listed below.
[0422] Nucleic acid sequence of the heavy chain variable region H9v of H9L8 (360 bp):
[0423] The amino acid sequence of the heavy chain variable region H9v of H9L8 (120aa):
[0424] Nucleic acid sequence of the light chain variable region L8v of H9L8 (321 bp):
[0425] The amino acid sequence of the light chain variable region L8v of H9L8 (107aa):
[0426] The nucleic acid sequence of the heavy chain variable region H9v of H9L9 is identical to the nucleic acid sequence of the heavy chain variable region H9v of H9L8, namely, SEQ ID NO: 1.
[0427] The amino acid sequence of the heavy chain variable region H9v of H9L9 is identical to the amino acid sequence of the heavy chain variable region H9v of H9L8, namely, SEQ ID NO: 2.
[0428] Nucleic acid sequence of the light chain variable region L9v of H9L9 (321 bp):
[0429] The amino acid sequence of the light chain variable region L9v of H9L9 (107 bp):
[0430] The nucleic acid sequence of the heavy chain variable region H9v of H9L10 is identical to the nucleic acid sequence of the heavy chain variable region H9v of H9L8, namely, SEQ ID NO: 1.
[0431] The amino acid sequence of the heavy chain variable region H9v of H9L10 is identical to the amino acid sequence of the heavy chain variable region H9v of H9L8, namely, SEQ ID NO: 2.
[0432] Nucleic acid sequence of the light chain variable region L10v of H9L10 (321 bp):
[0433] Amino acid sequence of the light chain variable region L10v of H9L10 (107 bp):
[0434] The amino acid sequence of the CDR of antibody H9L8 is as follows (according to the IMGT numbering system):
[0435] HCDR1:GGSISDYY(SEQ ID NO:9);
[0436] HCDR2: INYRGTT (SEQ ID NO: 10);
[0437] HCDR3:AFGYSDYEYDWFDP(SEQ ID NO:11);
[0438] LCDR1: QTISSY(SEQ ID NO:12);
[0439] LCDR2: DAS (SEQ ID NO: 13);
[0440] LCDR3: QQRSNWPIT (SEQ ID NO: 14).
[0441] The amino acid sequence of the CDR of antibody H9L9 is as follows (according to the IMGT numbering system):
[0442] HCDR1:GGSISDYY(SEQ ID NO:9);
[0443] HCDR2: INYRGTT (SEQ ID NO: 10);
[0444] HCDR3:AFGYSDYEYDWFDP(SEQ ID NO:11);
[0445] LCDR1: QTISSY(SEQ ID NO:12);
[0446] LCDR2: DGS (SEQ ID NO: 15);
[0447] LCDR3: QQRSNWPLT (SEQ ID NO: 16).
[0448] The amino acid sequence of the CDR of antibody H9L10 is as follows (according to the IMGT numbering system):
[0449] HCDR1:GGSISDYY(SEQ ID NO:9);
[0450] HCDR2: INYRGTT (SEQ ID NO: 10);
[0451] HCDR3:AFGYSDYEYDWFDP(SEQ ID NO:11);
[0452] LCDR1: QSISSY(SEQ ID NO:17);
[0453] LCDR2: DGS (SEQ ID NO: 15);
[0454] LCDR3: QQRSNWPIT (SEQ ID NO: 14).
[0455] 2. Expression and Purification of Humanized Antibodies H9L8 (hG4WT), H9L9 (hG4WT), and H9L10 (hG4WT)
[0456] The heavy chain cDNA sequences of H9L8 (hG4WT), H9L9 (hG4WT), and H9L10 (hG4WT) (the variable region encoding sequence is shown in SEQ ID NO: 1; the constant region is the Ig gamma-4 chain C region), the light chain cDNA sequence of H9L8 (hG4WT) (the variable region encoding sequence is shown in SEQ ID NO: 3; the constant region is the human Ig kappa chain C region), the light chain cDNA sequence of H9L9 (hG4WT) (the variable region encoding sequence is shown in SEQ ID NO: 5; the constant region is the human Ig kappa chain C region), and the light chain cDNA sequence of H9L10 (hG4WT) (the variable region encoding sequence is shown in SEQ ID NO: 7; the constant region is the human Ig kappa chain C region) were cloned. The heavy and light chains of pUC57simple (H9, L8, L9, and L10) were digested with HindIII and EcoRI, respectively. The heavy and light chains were recovered by electrophoresis and subcloned into the pcDNA3.1 vector. The recombinant plasmids were then extracted and co-transfected into 293F cells. After 7 days of cell culture, the culture medium was centrifuged at high speed, the supernatant concentrated, and loaded onto a HiTrap MabSelect SuRe column. The protein was eluted in one step using Elution Buffer to recover the target sample, which was then exchanged with PBS.
[0457] H9L8 (hG4WT), H9L9 (hG4WT), or H9L10 (hG4WT) heavy chain constant region amino acid sequence:
[0458] H9L8 (hG4WT), H9L9 (hG4WT), or H9L10 (hG4WT) light chain constant region amino acid sequence:
[0459] 3. Expression and Purification of Humanized Antibody H9L8 (hG1WT)
[0460] Based on the variable region of the above antibody H9L8 (hG4WT), the Ig gamma-1 chain C region was used as the heavy chain constant region to obtain the antibody H9L8 (hG1WT).
[0461] H9L8 (hG1WT) heavy chain amino acid sequence
[0462] H9L8 (hG1WT) light chain amino acid sequence
[0463] Preparation Example 2: Preparation of human anti-egg lysosomal antibodies
[0464] Human anti-hen egg lysosomal IgG (anti-HEL, also known as human IgG, abbreviated as hIgG) was prepared from the variable region sequence of Fab F10.6.6, which was derived from the study published by Acierno et al. (Affinity maturation increases the stability and plasticity of the Fv domain of anti-protein antibodies) (Acierno et al. J Mol Biol. 2007; 374(1):130-46). The preparation method is as follows:
[0465] For human IgG, Nanjing GenScript Biopharmaceuticals was commissioned to perform amino acid codon optimization and gene synthesis for the heavy and light chain (full sequence or variable region) genes of the antibody. Following standard techniques outlined in the "Molecular Cloning Manual (3rd Edition)," standard molecular cloning techniques, including PCR, enzyme digestion, DNA gel recovery, ligation and transformation, colony PCR, or enzyme digestion analysis, were used to subclone the heavy and light chain genes into mammalian expression vectors for the antibody heavy and light chain, respectively. The recombinant heavy and light chain genes were then sequenced and analyzed. Following sequencing verification, large-scale endotoxin-free expression plasmids were prepared and transiently co-transfected into HEK293 cells for recombinant antibody expression. After 7 days of culture, the cell culture medium was harvested and affinity purified using an rProtein A column (GE). The harvested antibody sample was then analyzed for quality using standard analytical techniques, such as SDS-PAGE and SEC-HPLC.
[0466] Unless otherwise specified, the hIgG1, hIgG1DM and hIgG4WT used in the present invention are anti-HEL isotype control antibodies with hIgG1, hG1DM and hG4WT constant region sequences, respectively, and were prepared in the laboratory of Zhongshan Kangfang Biopharmaceutical Co., Ltd.
[0467] Preparation Example 3: Design and Preparation of Anti-CD73 Antibodies
[0468] 1. The sequences and preparation methods of the anti-CD73 antibodies 19F3, 19F3H1L1, 19F3H2L2, and 19F3H2L3 are based on Chinese patent CN113527489A, and some of the sequences are cited below.
[0469] 19F3, 19F3H1L1, 19F3H2L2, and 19F3H2L3 share the same three heavy chain CDRs and three light chain CDRs (according to the IMGT numbering system):
[0470] HCDR1: GYSFTGYT (SEQ ID NO: 25)
[0471] HCDR2: INPYNAGT (SEQ ID NO: 26)
[0472] HCDR3:ARSEYRYGGDYFDY(SEQ ID NO:27)
[0473] LCDR1:QSLLNSSNQKNY(SEQ ID NO:28)
[0474] LCDR2:FAS (SEQ ID NO: 29)
[0475] LCDR3:QQHYDTPYT (SEQ ID NO: 30)
[0476] The amino acid sequence of the 19F3 heavy chain variable region, with the CDR sequences underlined:
[0477] The amino acid sequence of the 19F3 light chain variable region, with the CDR sequence underlined:
[0478] Amino acid sequence of the heavy chain variable region of 19F3H1L1, with the CDR sequences underlined:
[0479] Amino acid sequence of the light chain variable region of 19F3H1L1, with the CDR sequence underlined:
[0480] Amino acid sequence of the heavy chain variable region of 19F3H2L2, with the CDR sequences underlined:
[0481] Amino acid sequence of the light chain variable region of 19F3H2L2, with the CDR sequences underlined:
[0482] Amino acid sequence of the heavy chain variable region of 19F3H2L3, with the CDR sequences underlined:
[0483] Amino acid sequence of the light chain variable region of 19F3H2L3, with the CDR sequences underlined:
[0484] 2. Preparation of Humanized Antibody 19F3H2L3
[0485] The heavy chain constant region all used the Ig gamma-1 chain C region; the light chain constant region all used the Ig kappa chain C region.
[0486] The heavy and light chain cDNAs of 19F3H2L3 were cloned into the pUC57simple vector (provided by GenScript), generating pUC57simple-19F3H2 and pUC57simple-19F3L3, respectively. Following standard techniques outlined in the Molecular Cloning Manual (3rd Edition), the synthesized full-length heavy and light chain genes were digested with EcoRI and HindIII and subcloned into the expression vector pcDNA3.1 using restriction enzymes (EcoRI and HindIII) to generate expression plasmids pcDNA3.1-19F3H2 and pcDNA3.1-19F3L3. The heavy and light chain genes from the recombinant expression plasmids were sequenced and analyzed. Subsequently, the designed recombinant plasmids containing the corresponding heavy and light chain genes (pcDNA3.1-19F3H2 / pcDNA3.1-19F3L3) were co-transfected into 293F cells, and the culture medium was collected for purification. After sequencing verification, an endotoxin-free expression plasmid was prepared and transiently transfected into HEK293 cells for antibody expression. After 7 days of culture, the cell culture fluid was collected and affinity purified using a Protein A column to obtain humanized antibodies.
[0487] 19F3H2L3 heavy chain amino acid sequence
[0488] 19F3H2L3 light chain amino acid sequence
[0489] 3. Preparation of humanized antibody 19F3H2L3 (hG1DM)
[0490] The light chain constant region of the antibody 19F3H2L3 (hG1DM) is the Ig kappa chain C region, as shown in SEQ ID NO: 19.
[0491] Based on the heavy chain constant region Ig gamma-1chain C region (SEQ ID NO: 18), a leucine to alanine point mutation (L234A) was introduced at position 234, and a leucine to alanine point mutation (L235A) was introduced at position 235 to obtain a humanized antibody named 19F3H2L3 (hG1DM).
[0492] The heavy and light chain cDNAs of 19F3H2L3 (hG1DM) were cloned into the pUC57simple vector (provided by GenScript), generating pUC57simple-19F3H2(hG1DM) and pUC57simple-19F3L3, respectively. Following standard techniques described in the Molecular Cloning Manual (3rd Edition), the synthesized full-length heavy and light chain genes were digested with EcoRI and HindIII and subcloned into the expression vector pcDNA3.1 using restriction enzymes (EcoRI and HindIII) to generate expression plasmids pcDNA3.1-19F3H2(hG1DM) and pcDNA3.1-19F3L3. The heavy and light chain genes from the recombinant expression plasmids were sequenced and analyzed. Subsequently, 293F cells were co-transfected with the corresponding light and heavy chain recombinant plasmid gene combinations (pcDNA3.1-19F3H2(hG1DM) / pcDNA3.1-19F3L3), and the culture medium was collected for purification. After sequencing verification, endotoxin-free expression plasmids were prepared and transiently transfected into HEK293 cells for antibody expression. After 7 days of culture, the cell culture medium was collected and affinity purified using a Protein A column to obtain the humanized antibody.
[0493] 19F3H2L3 (hG1DM) full-length heavy chain
[0494] 19F3H2L3 (hG1DM) full-length light chain
[0495] Preparation Example 4: Design and Preparation of Anti-CD73-Anti-LAG3 Bispecific Antibody
[0496] 1. Sequence Design
[0497] The structural model of the bispecific antibodies NTLAV2, NTLAV7, NTLAV8, LA5EV1, and LA5EV2 in the present invention belongs to the Morrison model (IgG-scFv), that is, the C-termini of the two heavy chains of an IgG antibody are connected to the scFv fragment of another antibody, and the main components of the heavy chain and light chain are designed as shown in Table 1 below.
[0498] In Table 1 above:
[0499] (1) Linker (GGGGS) 3 amino acid sequence:
[0500] (2) Linker (GGGGS) 4 amino acid sequence:
[0501] The "v" in the lower right corner refers to the variable region of the corresponding heavy chain or light chain. Where "v" is not marked, the corresponding heavy or light chain is the full-length version including the constant region. Unless otherwise specified, the amino acid sequences of these variable regions or full-length versions and their encoding nucleic acid sequences refer to the corresponding sequences described in the preparation examples above.
[0502] In the above Table 1, H9 in the scFv fragment of the antibody V (M), L8 V (M), 19FH2 V (M), 19L3 V (M1), 19L3 V (M2) is respectively in H9 V 、L8 V 、19FH2 V 、19L3 V On this basis, individual amino acids in its framework region were mutated, which effectively optimized the structure of the antibody and improved its effectiveness.
[0503] H9 V (M) amino acid sequence
[0504] L8 V (M) amino acid sequence
[0505] 19FH2 V (M) amino acid sequence
[0506] 19L3 V (M1) amino acid sequence
[0507] 19L3 V (M2) amino acid sequence
[0508] Based on the bispecific antibodies designed in Table 1 above, by introducing a leucine to alanine point mutation (L234A) at position 234 of the heavy chain, a leucine to alanine point mutation (L235A) at position 235, and a glycine to alanine point mutation (G237A) at position 237, bispecific antibodies containing the above mutation sites were obtained and named NTLAV2 (hG1TM), NTLAV7 (hG1TM), NTLAV8 (hG1TM), LA5EV1 (hG1TM) and LA5EV2 (hG1TM), respectively.
[0509] NTLAV2 (hG1TM) heavy chain amino acid sequence
[0510] NTLAV7 (hG1TM) heavy chain amino acid sequence
[0511] NTLAV8 (hG1TM) heavy chain amino acid sequence
[0512] LA5EV1(hG1TM) heavy chain amino acid sequence
[0513] LA5EV2(hG1TM) heavy chain amino acid sequence
[0514] Unless otherwise specified, in the following experiments and examples, the above-mentioned bispecific antibodies carrying mutation sites, NTLAV2 (hG1TM), NTLAV7 (hG1TM), NTLAV8 (hG1TM), LA5EV1 (hG1TM) and LA5EV2 (hG1TM), are referred to as NTLAV2, NTLAV7, NTLAV8, LA5EV1 and LA5EV2, respectively.
[0515] 2. Antibody Expression and Purification
[0516] The heavy chain cDNA sequences and light chain cDNA sequences of NTLAV2, NTLAV7, NTLAV8, LA5EV1, and LA5EV2 were cloned into the pUC57simple (provided by GenScript) vector to obtain pUC57simple-NTLAV2H / pUC57simple-NTLAV2L, pUC57simple-NTLAV7H / pUC57simple-NTLAV7L, pUC57simple-NTLAV8H / pUC57simple-NTLAV8L, pUC57simple-LA5EV1H / pUC57simple-LA5EV1L, and pUC57simple-LA5EV2H / pUC57simple-LA5EV2H plasmids, respectively.
[0517] Plasmids pUC57simple-NTLAV2H / pUC57simple-NTLAV2L, pUC57simple-NTLAV7H / pUC57simple-NTLAV7L, pUC57simple-NTLAV8H / pUC57simple-NTLAV8L, pUC57simple-LA5EV1H / pUC57simple-LA5EV1L, and pUC57simple-LA5EV2H / pUC57simple-LA5EV2H were digested with HindIII and EcoRI, and the resulting heavy and light chains were recovered by electrophoresis and subcloned into the pcDNA3.1 vector. The recombinant plasmids were extracted and co-transfected into 293F cells. After 7 days of cell culture, the culture medium was centrifuged at high speed, the supernatant was concentrated, and the sample was loaded onto a HiTrap MabSelect SuRe column. The protein was eluted in one step with Elution Buffer to recover the target sample, and the buffer was exchanged with PBS.
[0518] Example 1: ELISA method to determine the binding activity of anti-LAG3 antibodies and antigens
[0519] ELISA plates coated with human LAG3-mG1Fc at 2 μg / mL were incubated overnight at 4°C. The plate was then washed once with PBST and blocked with 1% BSA in PBS for 2 hours at 37°C. After blocking, the plate was washed three times with PBST. Antibodies were added in a serial dilution of PBST (see Table 2 for the antibody dilution series). The plate was incubated at 37°C for 30 minutes and washed three times with PBST. After washing, a 1:5000 dilution of HRP-conjugated goat anti-human IgG (H+L) (Jackson, Cat. No. 109-035-088) secondary antibody was added and incubated at 37°C for 30 minutes. After incubation, the plate was washed four times with PBST. TMB (Neogen, 308177) was added for 5 minutes in the dark, and the color reaction was terminated with stop solution. Immediately place the plate into a microplate reader and read the OD values of each well at 450 nm. Analyze the data using SoftMax Pro 6.2.1 software.
[0520] The test results are shown in Table 2 and Figure 1.
[0521] Table 2: ELISA detection of the binding of H9L8 (hG4WT), H9L9 (hG4WT), H9L10 (hG4WT) to the antigen human LAG3-mG1Fc
[0522] The results showed that antibodies H9L8 (hG4WT), H9L9 (hG4WT), and H9L10 (hG4WT) could effectively bind to the antigen human LAG3-mG1Fc. The binding efficiency was dose-dependent, and their binding activity was comparable to that of the positive control antibody Relatlimab.
[0523] Example 2: Flow cytometry detection of the binding activity of anti-LAG3 antibodies to the cell surface antigen human LAG3
[0524] Antibody labeling and flow cytometry detection: 293T-LAG3 cells expressing human LAG3 antigen were digested using conventional trypsin digestion method, and the number of cells in each collection tube was 3×10 5 LAG3 antibody dilutions were prepared in 1% PBSA (PBS containing 1% BSA) to final concentrations of 0.0123 nM, 0.123 nM, 1.23 nM, 3.7 nM, 11.1 nM, 33.3 nM, 100 nM, and 300 nM, respectively. The cells were incubated on ice with LAG3-expressing 293T-LAG3 cells for 1 hour. After washing several times with 1% PBSA by centrifugation, 100 μL of FITC goat anti-human IgG (Jackson, Cat. No. 109-095-098) (1:300 dilution) was added to each tube and incubated on ice for 40 minutes in the dark. After washing once with 1% PBSA, the cells were resuspended in 200 μL of 1% PBSA and fluorescence signals were detected using the FITC channel on a flow cytometer.
[0525] The binding results of humanized anti-LAG3 antibodies to 293T-LAG3 cells are shown in Figure 2. The EC values of each anti-LAG3 antibody binding to the 293T-LAG3 surface antigen are shown in Figure 2. 50 As shown in Table 3.
[0526] Table 3: Flow cytometry analysis of the binding activity of anti-LAG3 antibodies to 293T-LAG3 surface antigens
[0527] As shown in Figure 2, anti-LAG3 antibodies can effectively bind to the target LAG3 protein on the surface of 293T-LAG3 cells, and the binding activity of anti-LAG3 antibodies H9L8 (hG4WT), H9L9 (hG4WT), and H9L10 (hG4WT) to the 293T-LAG3 cell surface antigen is comparable to that of the positive control antibody Relatlimab.
[0528] Example 3: Competitive flow cytometry determination of the competitive binding of anti-LAG3 antibodies to MHC II on the surface of Raji cell membranes for human LAG3-mG1Fc antigen
[0529] Raji cells (culture medium: 1640 + 10% FBS) (Cell Resource Center, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, catalog number: TCHu 44) were plated at 300,000 cells / sample into EP tubes. 1000 μL of 1% PBSA (PBS containing 1% BSA) was added, and the tubes were centrifuged at 600 × g for 5 minutes, and the supernatant discarded. hIgG1 (Akeso Biopharm, lot number: 20190410) was added to each tube at a final concentration of 300 nM, and 100 μL per tube was incubated on ice for 1 hour. After incubation, 200 μL of 1% PBSA was added to the Raji cells, and the cells were centrifuged at 600 × g for 5 minutes, and the supernatant discarded. According to the experimental design, take another clean EP tube and add the corresponding concentration of diluted antibodies, 60 μL per tube, and add 60 μL of human LAG3-mG1Fc (prepared by Kangfang Bio, batch number: 20190508) to the corresponding antibody tube, mix well, and pre-incubate on ice for 30 minutes to make the final antibody concentrations of 300 nM, 100 nM, 33.3 nM, 11.1 nM, 3.7 nM, 1.23 nM, 0.123 nM and 0.0123 nM, and the final concentration of human LAG3-mG1Fc is 3 nM. Add 100 μL of pre-incubated antibody and protein mixture to the cells, mix well and incubate on ice in the dark for 1 hour; add 200 μL of 1% PBSA, centrifuge at 600 × g for 5 minutes, remove the supernatant, and wash twice; add 100 μL of APC anti mouse antibody (purchased from Biolegend, product number: 405308) (1:400 dilution), mix well and incubate on ice in the dark for 40 minutes; add 200 μL of 1% PBSA, centrifuge at 600 × g for 5 minutes, remove the supernatant; resuspend the cells in 200 μL 1% PBSA / tube, transfer to the flow cytometry loading tube, and test on the machine.
[0530] The results are shown in Figure 3 and Table 4. The competitive binding EC values of antibodies Relalimab, H9L8 (hG4WT), H9L9 (hG4WT), and H9L10 (hG4WT) were calculated by fluorescence analysis and curve fitting. 50 They are 1.153nM, 1.459nM, 1.482nM and 1.435nM respectively.
[0531] Table 4: Fluorescence intensity analysis of Relalimab, H9L8 (hG4WT), H9L9 (hG4WT), H9L10 (hG4WT) competing with MHC II on the surface of Raji cells for binding to human LAG3-mG1Fc antigen by FACS
[0532] The results showed that antibodies H9L8 (hG4WT), H9L9 (hG4WT), and H9L10 (hG4WT) could competitively bind to LAG3 and effectively block the binding of LAG3 to MHC II on the surface of Raji cells in a dose-dependent manner. Their activity was comparable to that of the positive control antibody Relatlimab.
[0533] Example 4: Mixed Lymphocyte Reaction (MLR) Detection of the Biological Activity of Anti-LAG3 Antibodies in Promoting IFN-γ and IL-2 Secretion
[0534] 1. Bioactivity Assay of Anti-LAG3 Antibodies Promoting IFN-γ Secretion in Raji-PDL1 Mixed Lymphoid Reaction System
[0535] Raji-PDL1 cells were routinely subcultured; PBMC (from healthy donors) were revived and cultured with 10 mL of 1640 complete medium and stimulated with 0.5 μg / mL of SEB (Staphylococcal enterotoxin B) (Denotek, Catalog No.: S010201) for two days. Raji-PDL1 cells were treated with MMC (Stressmarq, Catalog No.: SIH-246-10MG) at a working concentration of 2 μg / mL and placed in a 37°C, 5% CO2 carbon dioxide incubator for 1 hour; PBMCs stimulated with SEB for 2 days and Raji-PDL1 cells treated with MMC for 1 hour were collected, washed twice with PBS, and then resuspended and counted in complete medium (i.e., RPMI 1640 + 10% FBS). PBMCs and Raji-PDL1 were each plated at 10×10 4 Cells were added to a U-shaped 96-well plate (Corning, Model 3799) and co-cultured. Antibodies were added according to the experimental design (final concentrations of each antibody were 300 nM, 30 nM, and 3 nM when used alone or in combination) and co-cultured in an incubator for 3 days. After 3 days, the cells were centrifuged at 250 x g for 5 minutes, and the cell culture supernatant was collected for IFN-γ detection by ELISA.
[0536] As shown in Figure 4, mixed culture of human PBMC and Raji-PDL1 cells promoted the secretion of IFN-γ by PBMC, and the simultaneous addition of antibodies to the mixed culture system significantly induced PBMC to further secrete IFN-γ. In terms of the activity level of promoting IFN-γ secretion, the anti-LAG3 antibodies H9L8 (hG4WT), H9L9 (hG4WT), and H9L10 (hG4WT) combined with 14C12H1L1 (hG1TM), and the positive control antibody Relatlimab combined with 14C12H1L1 (hG1TM) all promoted IFN-γ secretion, and their activities were comparable.
[0537] 2. Bioactivity Detection of Anti-LAG3 Antibodies in Promoting IL-2 Secretion in Raji-PDL1 Mixed Lymphoid Reaction System
[0538] Raji-PDL1 cells were routinely subcultured; PBMCs were revived and cultured with 10 mL of 1640 complete medium, and stimulated for two days with the addition of 0.5 μg / mL of SEB (Staphylococcal enterotoxin B, purchased from Denotek, catalog number: S010201). Raji-PDL1 cells were treated with MMC (Stressmarq, catalog number: SIH-246-10MG) at a working concentration of 2 μg / mL and placed in a 37°C, 5% CO2 carbon dioxide incubator for 1 hour. PBMCs stimulated with SEB for 2 days and Raji-PDL1 cells treated with MMC for 1 hour were collected, washed twice with PBS, and then resuspended and counted in complete medium (i.e., RPMI 1640 + 10% FBS). PBMCs and Raji-PDL1 were each plated at 10×10 4 Cells were added to a U-shaped 96-well plate (Corning, Model 3799) and co-cultured. Antibodies were added according to the experimental design (final concentrations of each antibody were 300 nM, 30 nM, and 3 nM, respectively, when used alone or in combination) and co-cultured for 3 days. After 3 days, the cells were centrifuged at 250x for 5 minutes, and the cell culture supernatant was collected for IL-2 detection by ELISA.
[0539] As shown in Figure 5, mixed culture of human PBMC (from healthy donors) and Raji-PDL1 cells promoted the secretion of IL-2 by PBMC to a certain extent. The simultaneous addition of antibodies to the mixed culture system could significantly induce PBMC to further secrete IL-2, with a significant dose-dependent relationship. In terms of the level of IL-2 secretion-promoting activity, the anti-LAG3 antibodies H9L8 (hG4WT), H9L9 (hG4WT), and H9L10 (hG4WT) combined with 14C12H1L1 (hG1TM), and the positive control Relatlimab combined with 14C12H1L1 (hG1TM) could all promote IL-2 secretion, and their activities were comparable.
[0540] Example 5: Evaluation of the biological activity of anti-LAG3 antibodies in blocking the interaction between LAG3 and MHC-II (reporter gene method)
[0541] Using Jurkat-NFAT-PD1-LAG3 cells and Raji cells as a reporter gene system, the addition of the SEE superantigen activated the TCR-NFAT signaling pathway and induced luciferase expression. LAG3 on Jurkat cells then bound to MHC-II on Raji cells, inhibiting the NFAT signaling pathway and downregulating luciferase expression. The antibody specifically binds to LAG3, relieving this inhibition and upregulating luciferase expression.
[0542] Jurkat-NFAT-PD1-LAG3 cells and Raji cells (purchased from the Cell Resource Center of Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, catalog number: TCHu 44) were collected and centrifuged at 110×g for 5 min to remove the supernatant. The cells were resuspended in 1640 μL of 10% FBS medium and counted. Jurkat-NFAT-PD1-LAG3 cells were cultured at 10 5 Cells / well were seeded into a black-bottom 96-well plate (Corning, model: 3916) at 30 μL / well. Antibodies (final concentrations of 0.3 nM, 3 nM, and 300 nM) were added according to the experimental design at 10 μL / well and pre-incubated in a 37°C, 5% CO2 incubator for 30 min. At the same time, SEE (Staphylococcal Enterotoxins E, purchased from Toxin Technology, catalog number: ET404) (final concentration 0.05 ng / mL) was added to Raji cells and incubated in a 37°C, 5% CO2 incubator for 30 min. After 30 min, 2×10 cells were plated and the SEE-treated Raji cells were plated. 4 Add 40 μL / well of cells to the 96-well plate containing Jurkat-NFAT-PD1-LAG3 cells, and the final volume of the system is 80 μL. Mix well and incubate in a 37°C, 5% CO2 incubator for 6 hours. After incubation, remove the culture plate, equilibrate to room temperature, and add Bright-Glo TM Luciferase Assay System (Promega, Cat. No. E2650) was used at 80 μL / well. Incubate in the dark for 2 minutes and read the RLU value. The isotype control hG4WT (hIgG4) was manufactured by Kangfang Bio, Lot No. 20190910.
[0543] The results are shown in Figure 6 . The anti-LAG3 antibodies H9L8 (hG4WT), H9L9 (hG4WT), H9L10 (hG4WT), and the positive control antibody Relatlimab can all block the interaction between LAG3 and MHC-II and upregulate the expression of luciferase. The activities of the anti-LAG3 antibodies H9L8 (hG4WT), H9L9 (hG4WT), and H9L10 (hG4WT) are all superior to those of the control antibody Relatlimab.
[0544] Example 6: ELISA method to determine the binding activity of anti-CD73-anti-LAG3 bispecific antibody to antigen
[0545] 1. The binding activity of LA5EV1, LA5EV2, NTLAV2, NTLAV7, and NTLAV8 to the antigen NT5E-His was determined by indirect ELISA. The specific method is as follows:
[0546] ELISA plates coated with NT5E-His at 1 μg / mL were incubated overnight at 4°C. The antigen-coated plates were then washed once with PBST and blocked with 1% BSA in PBS for 2 hours at 37°C. After blocking, the plates were washed three times with PBST. Antibodies were added in a gradient of dilutions in PBST (see Tables 5 to 7 for the antibody dilution gradient). The plates were incubated at 37°C for 30 minutes, and washed three times with PBST. After washing, HRP-conjugated goat anti-human IgG FC (H+L) (Jackson, Cat. No. 109-035-098) was added at a 1:5000 dilution, and the plates were incubated at 37°C for 30 minutes. After incubation, the plates were washed four times with PBST, and TMB (Neogen, 308177) was added for color development for 5 minutes in the dark. The color reaction was terminated with stop solution. Immediately place the plate into a microplate reader and read the OD values of each well at 450 nm. Analyze the data using SoftMax Pro 6.2.1 software.
[0547] The results are shown in Tables 5 to 7 and Figures 7 to 9.
[0548] The results showed that under the same experimental conditions, LA5EV1, LA5EV2, NTLAV2, NTLAV7, NTLAV8, and 19F3H2L3 (hG1DM) could all effectively bind to the antigen NT5E-His, and their binding efficiency was dose-dependent.
[0549] 2. The binding activity of LA5EV1, LA5EV2, NTLAV2, NTLAV7, and NTLAV8 to the antigen huLAG3-mG1Fc was determined by indirect ELISA. The specific method is as follows:
[0550] ELISA plates coated with huLAG3-mG1Fc at 2 μg / mL were incubated overnight at 4°C. The antigen-coated plates were then washed once with PBST and blocked with 1% BSA in PBS for 2 hours at 37°C. After blocking, the plates were washed three times with PBST. Antibodies were serially diluted in PBST (see Tables 8 to 10 for the antibody dilution series). The plates were incubated at 37°C for 30 minutes, and washed three times with PBST. After washing, HRP-conjugated goat anti-human IgG FC (H+L) (Jackson, Cat. No. 109-035-098) secondary antibody was added at a 1:5000 dilution and incubated at 37°C for 30 minutes. After incubation, the plates were washed four times with PBST, and TMB (Neogen, 308177) was added for color development for 5 minutes in the dark. The color reaction was terminated with stop solution. Immediately place the plate into a microplate reader and read the OD values of each well at 450 nm. Analyze the data using SoftMax Pro 6.2.1 software.
[0551] The test results are shown in Tables 8 to 10 and Figures 10 to 12.
[0552] The results showed that under the same experimental conditions, LA5EV1, LA5EV2, NTLAV2, NTLAV7, NTLAV8, and Relatlimab were all able to effectively bind to the antigen huLAG3-mG1Fc, and their binding efficiency was dose-dependent.
[0553] Example 7: Determination of kinetic parameters of humanized antibodies LA5EV1, LA5EV2, NTLAV2, NTLAV7, and NTLAV8
[0554] 1. Determination of Kinetic Parameters for Binding of Humanized Antibodies LA5EV1, LA5EV2, NTLAV2, NTLAV7, and NTLAV8 to hNT5E(1-552)-His
[0555] The sample dilution buffer consisted of PBS, 0.02% Tween-20, 0.1% BSA, pH 7.4. 5 μg / ml of hNT5E(1-552)-His was immobilized on the HIS1K sensor at a fixed height of 0.15 nm. The sensor was equilibrated in the buffer for 60 s. The sensor-immobilized hNT5E(1-552)-His bound to various antibodies at concentrations ranging from 2.469 to 200 nM (threefold dilutions) for 120 s, and the antibodies dissociated in the buffer for 300 s. The sensor was regenerated using 10 mM glycine, pH 1.7, for 5 s, and repeated four times. The sample plate was shaken at a rate of 1000 rpm, the detection temperature was 37°C, and the frequency was 5.0 Hz. Data were analyzed using a 1:1 model fit to obtain affinity constants. Data acquisition software was Fortebio Data Acquisition 12.0, and data analysis software was Fortebio Data Analysis 12.0.
[0556] Table 11: Kinetic parameters for binding of humanized antibodies LA5EV1, LA5EV2, NTLAV2, NTLAV7, and NTLAV8 to hNT5E(1-552)-His
[0557] K D is the affinity constant; kon is the antigen-antibody binding rate; kdis is the antigen-antibody dissociation rate; K D =kdis / kon.
[0558] The results are shown in Table 11 and Figures 13 to 18.
[0559] The results showed that the humanized antibodies LA5EV1, LA5EV2, NTLAV2, NTLAV7, and NTLAV8 all had good affinity with the antigen hNT5E(1-552)-His.
[0560] 2. Determination of Kinetic Parameters for Binding of Humanized Antibodies LA5EV1, LA5EV2, NTLAV2, NTLAV7, and NTLAV8 to huLAG3-mG1Fc
[0561] The sample dilution buffer consisted of PBS, 0.02% Tween-20, 0.1% BSA, pH 7.4. 10 μg / ml huLAG3-mG1Fc was immobilized on the AMC sensor at a fixed height of 0.8 nm. The sensor was equilibrated in the buffer for 60 s. The immobilized huLAG3-mG1Fc was then bound to various antibodies at concentrations ranging from 6.17 to 500 nM (threefold dilutions) for 100 s, and the antibodies were allowed to dissociate in the buffer for 400 s. The sensor was regenerated using 10 mM glycine, pH 1.7, for 5 s, and repeated four times. The sample plate was shaken at a rate of 1000 rpm, the detection temperature was 30°C, and the frequency was 5.0 Hz. Data were analyzed using a 1:1 model fit to obtain affinity constants. Data acquisition and analysis software were Fortebio Data Acquisition 12.0 and Fortebio Data Analysis 12.0.
[0562] The results are shown in Table 12 and Figures 19 to 25.
[0563] The results showed that the humanized antibodies LA5EV1, LA5EV2, NTLAV2, NTLAV7, and NTLAV8 all had good affinity with the antigen huLAG3-mG1Fc.
[0564] Table 12: Kinetic parameters for binding of humanized antibodies LA5EV1, LA5EV2, NTLAV2, NTLAV7, and NTLAV8 to huLAG3-mG1Fc
[0565] Example 8: FACS detection of the binding activity of anti-CD73-anti-LAG3 bispecific antibody to CD73 / LAG3 antigen
[0566] 1. FACS detection of the binding activity of anti-CD73-anti-LAG3 bispecific antibody to LAG3 on the surface of 293T-LAG3 membrane
[0567] 293T-LAG3 cells in the logarithmic growth phase were collected and counted at 3×10 5 Transfer the cells to a 96-well flow cytometry plate, add 100 μL of 1% PBSA, centrifuge at 350 × g for 5 minutes, and remove the supernatant. Add 100 μL of antibodies diluted in 1% PBSA (final concentrations are 300 nM, 100 nM, 33.33 nM, 11.11 nM, 3.7 nM, 1.23 nM, 0.41 nM, 0.041 nM, 0.0041 nM, and 0.00041 nM), mix gently, and incubate on ice for 1 hour. Add 200 μL of 1% PBSA, centrifuge at 350 × g for 5 minutes, remove the supernatant, and repeat the washing twice. Add 300-fold diluted Alexa Resuspend and mix the cells with 647-conjugated mouse anti-human IgG secondary antibody (Southern Biotech, Cat. No. 9040-31) and incubate on ice in the dark for 0.5 h. Add 200 μL of 1% PBSA and centrifuge at 350 × g for 5 min. Remove the supernatant and repeat the wash twice. Resuspend the cell pellet in 200 μL of 1% PBSA and analyze on an analyzer.
[0568] The experimental results are shown in Table 13 and Figure 26.
[0569] The results showed that NTLAV8, LA5EV2, H9L8 (hG4WT), and Relatlimab could all specifically bind to the LAG3 receptor on the surface of 293T-LAG3 cell membranes.
[0570] Table 13: FACS detection of the binding activity of NTLAV8, LA5EV2, H9L8 (hG4WT), and Relatlimab to LAG3 on the surface of 293T-LAG3 cells
[0571] 2. FACS detection of the binding activity of anti-CD73-anti-LAG3 bispecific antibody to CD73 on the surface of U87-MG cell membrane
[0572] U87-MG cells (ATCC, catalog number: HTB-14) were collected during the logarithmic growth phase and plated at 3×10 5 Transfer the cells to a 96-well plate, add 200 μL of 1% PBSA, centrifuge at 750 × g for 5 min, and remove the supernatant. Add 100 μL of antibodies diluted in 1% PBSA (final concentrations of 300 nM, 100 nM, 33.33 nM, 11.11 nM, 3.7 nM, 1.23 nM, 0.41 nM, 0.041 nM, 0.0041 nM, and 0.00041 nM, respectively), mix gently, and incubate on ice for 1 hour. Add 200 μL of 1% PBSA, centrifuge at 750 × g for 5 min, remove the supernatant, and repeat washing twice. Add 300-fold diluted Alexa Resuspend and mix the 647-conjugated mouse anti-human IgG secondary antibody (Southern Biotech, Cat. No. 9040-31) and incubate on ice in the dark for 0.5 h. Add 100 μL of 1% PBSA and centrifuge at 750 x g for 5 min. Remove the supernatant and wash twice with 200 μL of 1% PBSA. Resuspend the cell pellet in 200 μL of 1% PBSA and analyze on an analyzer.
[0573] The experimental results are shown in Table 14 and Figure 27.
[0574] The results showed that NTLAV8, LA5EV2, 19F3H2L3 (hG1DM), and CPI-006 could all specifically bind to CD73 on the surface of U87-MG cell membranes, and the binding ability of NTLAV8 and LA5EV2 to CD73 on the surface of U87-MG cell membranes was stronger than that of the positive control CPI-006.
[0575] Table 14: FACS detection of the binding activity of NTLAV8, LA5EV2, 19F3H2L3 (hG1DM), and CPI-006 to CD73 on the surface of U87-MG cells
[0576] Example 9: FACS detection of competitive binding of anti-CD73-anti-LAG3 bispecific antibody to human LAG3-mG1Fc antigen with MHC II on Raji cell membrane
[0577] Antibodies and LAG3-mG1Fc were diluted according to the experimental design and mixed evenly in a 1:1 ratio, so that the final concentration of LAG3-mG1Fc was 3 nM and the final concentration of antibodies was 300 nM, 100 nM, 33.33 nM, 11.11 nM, 3.7 nM, 1.23 nM, 0.41 nM, 0.041 nM, 0.0041 nM or 0.00041 nM, and incubated on ice for 30 min. Raji cells were routinely collected and 3 × 10 5 Cells were seeded into 96-well conical-bottom plates, supplemented with 1% PBSA, centrifuged at 500 × g for 5 minutes, and the supernatant discarded. A 150 μg / mL mouse IgG isotype control (Thermofisher, Cat. No. 10400C) was added and incubated on ice for 20 minutes. The cells were then centrifuged at 500 × g for 5 minutes, and the supernatant discarded. Cells were resuspended in 100 μL of antibody and protein preincubation buffer. Blank, negative, and isotype controls were prepared and incubated on ice for 1 hour in the dark. Cells were then centrifuged at 500 × g for 5 minutes in 100 μL of 1% PBSA and washed twice with 200 μL of 1% PBSA. Cells were resuspended in 100 μL of a 300-fold diluted APC-conjugated goat anti-mouse IgG secondary antibody (Biolegend, Cat. No. 405308). For blank controls, cells were resuspended in 100 μL of 1% PBSA and incubated on ice for 30 minutes in the dark. Add 100 μL 1% PBSA, centrifuge at 500×g for 5 min, remove the supernatant, and wash twice with 200 μL 1% PBSA; add 200 μL 1% PBSA to resuspend the cells and test on the instrument.
[0578] EC of each sample 50The values are shown in Table 15. The results are shown in Figure 28. The results showed that antibodies NTLAV8, LA5EV2, Relatlimab (positive control), and H9L8 (hG4WT) could compete for binding to human LAG3-mG1Fc and effectively block the binding of LAG3-mG1Fc to MHC II on the surface of Raji cells in a dose-dependent manner.
[0579] Table 15: Fluorescence intensity analysis of competitive binding of NTLAV8, LA5EV2, Relatlimab, H9L8 to MHC II on the surface of Raji cells by FACS
[0580] Example 10: Anti-CD73-anti-LAG3 bispecific antibody blocking experiment
[0581] Jurkat-NFAT-PD1-LAG3 (Kangfang Biotech) cells and Raji cells (Cell Resource Center, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, catalog number: TCHu 44) were collected and centrifuged at 110×g for 5 min. The supernatant was removed and the cells were resuspended in 1640 medium (containing 10% FBS) and counted. Jurkat-NFAT-PD1-LAG3 cells were plated at 10×10 4 Cells / well were seeded into black-bottom 96-well plates (Corning, model: 3916); antibodies were added according to the experimental design (final concentrations were 900nM, 300nM, 100nM, 33.3nM, 3.3nM, 0.33nM, 0.03nM, and 0.003nM, respectively), and the cells were pre-incubated in a 37°C, 5% CO2 incubator for 30 minutes. SEE (Staphylococcal enterotoxin E) (final concentration 0.05ng / mL, Toxin Technology, catalog number: ET404) and Raji cells were incubated in a 37°C, 5% CO2 incubator for 30 minutes. After incubation for 30 minutes, Raji cells were plated at 2×10 4 Add 10 cells / well to a 96-well plate (final volume: 80 μL), mix thoroughly, and incubate in a 37°C, 5% CO2 incubator for 16 hours. Remove the plate, equilibrate to room temperature, and add 80 μL / well of the Firefly Glo Luciferase Reporter Gene Assay Kit (Yeasen, Catalog No. 11404ES80). Incubate in the dark for 2 minutes, and then read the RLU values.
[0582] The results are shown in Figure 29.
[0583] The results showed that both NTLAV8 and H9L8 (hG4WT) could effectively block the inhibition of signaling pathways mediated by the interaction between LAG3 and MHCII.
[0584] Example 11: Detection of Inhibition of CD73 Enzyme Activity on Cell Membrane Surface by Anti-CD73-Anti-LAG3 Bispecific Antibodies
[0585] The experimental setup was divided into the following groups:
[0586] ATP control group, AMP+ATP control group, negative control group (cells+AMP+ATP), APCP control group (cells+APCP+AMP+ATP), isotype control group (cells+isotype control antibody+AMP+ATP), and antibody group (cells+corresponding antibody+AMP+ATP).
[0587] Among them: ATP refers to adenosine triphosphate, AMP refers to adenosine monophosphate, and APCP refers to adenosine 5'-(α,β-methylene adenosine-5'-diphosphate), which is a specific CD73 inhibitor.
[0588] Take the logarithmic phase U87-MG cells (ATCC, catalog number: HTB-14) in good condition, resuspend the cells in assay medium (i.e. serum-free RPMI-1640 culture medium), and count the cells; 4 U87-MG cells were seeded into 96-well plates at 60 μL / well. 120 μM APCP and diluted antibodies were prepared with assay medium (starting at 300 nM, serially diluted 3-fold (the last two low concentrations were diluted 10-fold)). The above APCP or diluted antibodies were added to the 96-well plate at 60 μL / well and incubated at 37°C for 1 hour. Then, AMP (purchased from TCI, catalog number: A0158) diluted with assay medium to a concentration of 600 μM was added at 60 μL / well, mixed, and incubated for 3 hours. After 3 hours, 100 μL of cell culture supernatant was taken from each well and transferred to a plate containing 40 μL / well CTG ( One Solution Assay (Promega, Catalog No. G8461) was placed in a new 96-well plate, gently tapped to mix, and incubated at room temperature in the dark for 5 minutes. After 5 minutes, 10 μL / well of ATP (5'-ATP 2Na Hydrate, purchased from TCI, Catalog No. A0157) prepared in TM buffer (Kongfang Bio) to a concentration of 300 μM was added. Gently tapped to mix, and incubated at room temperature in the dark for 5 minutes. Finally, the data were read using a multi-label microplate reader (PerkinElmer, Model: 2140-0020).
[0589] The experimental results are shown in Table 16 and Figure 30. The results showed that the anti-CD73-anti-LAG3 antibodies LA5EV2, NTLAV2, NTLAV8 and the CD73 target positive control drug MEDI9447 were able to dose-dependently inhibit the activity of the CD73 enzyme endogenously expressed in U87-MG to catalyze AMP to adenosine, thereby dose-dependently reducing the mean fluorescence intensity RLU value, and the activity of LA5EV2 and NTLAV8 in inhibiting CD73 enzyme activity was stronger than that of MEDI9447.
[0590] Table 16: Anti-CD73-anti-LAG3 bispecific antibodies inhibit the enzymatic activity of endogenously expressed CD73 in cells
[0591] Example 12: Mixed Lymphocyte Reaction (MLR) Detection of the Biological Activity of Anti-CD73-Anti-LAG3 Bispecific Antibody in Promoting IFN-γ Secretion
[0592] Raji-PDL1 cells (Kangfang Biotech) were routinely subcultured; at the same time, PBMCs (from healthy donors) were revived, cultured with 10 mL of 1640 complete medium, and stimulated for two days with SEB (Staphylococcal enterotoxin B, Toxin technology, catalog number: BT202) at a final concentration of 0.5 μg / mL. Two days later, Raji-PDL1 cells were routinely collected, resuspended in analysis medium (i.e., RPMI-1640 + 10% FBS), and MMC (Mito-mycin C, Stressmarq, catalog number: SIH-246-10MG) at a final concentration of 2 μg / mL was added and placed in a 37°C, 5% CO2 carbon dioxide incubator for 1 hour. PBMCs stimulated with SEB for two days and Raji-PDL1 cells treated with MMC for 1 hour were routinely collected, washed twice with analysis medium, resuspended in analysis medium and counted, and each was counted at 1×10 5 Cells were added to each well of a U-shaped 96-well plate (Corning, Model 3799) and co-cultured. AMP (5'-Adenylic Acid) (final concentration 200 μM, 200 TCI, Catalog No. A0158) and antibodies (final concentrations 300 nM, 30 nM, and 3 nM, respectively) were added as per the experimental design. A negative control (PBMC + Raji-PDL1 + AMP) and an isotype control group were also established. The cells were cultured in an incubator for three days. After three days, the cells were centrifuged at 250 × g for 5 minutes, and the cell culture supernatant was collected for IFN-γ detection by ELISA.
[0593] As shown in Figure 31, in the mixed culture system of human PBMC and Raji-PDL1 cells, the addition of antibodies can significantly induce IFN-γ secretion in the system. The activity of anti-CD73-anti-LAG3 antibodies LA5EV2 and NTLAV8 is better than that of CD73 single-target antibodies 19F3H2L3 (hG1DM), MEDI9447, and LAG-3 single-target control antibodies H9L8 (hG4WT) and Relatlimab.
[0594] Example 13: Anti-CD73-anti-LAG3 bispecific antibody may mediate phagocytic activity on CHO-K1-LAG3-CD73 target cells
[0595] Frozen MBMM (induced from C57 mice, purchased from Guangdong Yaokang Biotechnology Co., Ltd.) were revived and cultured overnight in DMEM+10% FBS+100 ng / mL M-CSF (Murine M-CSF, Peprotech, catalog number: 315-02).
[0596] Target cells CHO-K1-CD73-LAG3 (Kongfang Biotech) were collected, centrifuged at 170×g for 5 min, washed once with PBS, and counted. CFSE (Biolegend, Cat. No. 423801) was diluted with PBS to a final concentration of 2.5 μM; an appropriate amount of diluted CFSE was taken to resuspend the cells (staining density: 1×10 7 Cells / mL) were placed in an incubator and incubated for 20 minutes. 6 mL of DMEM complete medium (containing 10% FBS) was added to terminate the staining, centrifuged at 170 x g for 5 minutes, and the supernatant was discarded. 1 mL of DMEM complete medium was added and the cells were incubated in an incubator for 10 minutes. Antibodies were diluted with DMEM complete medium to final concentrations of 0.01 nM, 0.1 nM, 1 nM, 10 nM, and 100 nM, respectively. Negative controls and isotype controls were also set up. Target cells were plated at 1.5 × 10 5 Cells were added to a 96-well plate with pointed bottoms, and the antibody was added and mixed. The cells were incubated on ice for 40 minutes. The cells were centrifuged at 170 × g for 5 minutes and washed twice with DMEM complete medium. The macrophages (MBMM) were collected and centrifuged at 750 × g for 5 minutes. The supernatant was discarded and counted. The cells were resuspended in DMEM complete medium and the concentration of macrophages (5 × 10 4Cells were added to a 96-well conical-bottom plate containing target cells at a concentration of 100 μL / well. The cells were resuspended and mixed thoroughly, and then incubated in a 37°C incubator for 2 hours. 100 μL of room-temperature 1% PBSA was added to each well, centrifuged at 750 × g for 5 minutes, the supernatant discarded, and the cells were washed once with 200 μL of 1% PBSA. 100 μL / well of APC anti-mouse / human CD11b antibody (Biolegend, Cat. No. 101212) diluted 500-fold in 1% PBSA was added to the corresponding samples, mixed thoroughly, and incubated on ice for 40 minutes. 100 μL of 1% PBSA was added to each well, centrifuged at 750 × g for 5 minutes, the supernatant discarded, and the cells were washed once with 200 μL of 1% PBSA. The cells were resuspended in 200 μL of 1% PBSA and analyzed.
[0597] The results are shown in Figure 32.
[0598] The results showed that the CD73 single-target antibody 19F3H2L2 (G1WT) could promote the phagocytosis of CHO-K1-CD73-LAG3 cells by macrophages (MBMM) and had an ADCP effect; while the anti-CD73-anti-LAG3 antibodies LA5EV2 and NTLAV8 did not have ADCP effect.
[0599] Example 14: Pharmacodynamic Evaluation of Anti-CD73-Anti-LAG3 Bispecific Antibody in a Mouse Tumor Cell Subcutaneous Transplantation Model
[0600] To detect the in vivo tumor inhibitory activity of the anti-CD73-anti-LAG3 bispecific antibody, MIA-PaCa-2 cells (purchased from the cell bank of the China Center for Type Culture Collection) were first inoculated subcutaneously into 6-7 week old female NCG mice (purchased from Guangdong Yaokang Biotechnology Co., Ltd.). The day of grouping was defined as D0 day. The administration method was intraperitoneal injection (IP), once a week (weekly), for a total of 4 times. The modeling and specific administration methods are shown in Table 17. After administration, the length and width of the tumors in each group were measured, and the tumor volume was calculated. The tumor volume was calculated according to the following formula: tumor long diameter * tumor short diameter 2 Data were processed using GraphPad Prism 5 statistical software.
[0601] Table 17: Dosing regimen of anti-CD73-anti-LAG3 bispecific antibodies in the treatment of the MIA-PaCa-2 cell xenograft tumor model in NCG mice Note: The doses of 19F3H2L3 (hG1DM) 7.5 mg / kg, Relatlimab 7.5 mg / kg, and NTLAV8 10 mg / kg are equimolar concentrations.
[0602] The results are shown in Figure 33. The results show that compared with the isotype control antibody, the anti-CD73-anti-LAG3 bispecific antibody NTLAV8 and the control antibodies Relatlimab and 19F3H2L3 (hG1DM) can effectively inhibit the growth of mouse tumors. At the same dose, the anti-CD73-anti-LAG3 bispecific antibody NTLAV8 has a better tumor inhibition effect than the control antibody Relatlimab alone, 19F3H2L3 (hG1DM) alone, and the combination of Relatlimab and 19F3H2L3 (hG1DM).
[0603] In addition, as shown in FIG34 , the tumor-bearing mice had good tolerance to each test drug, and each group had no significant effect on the body weight of the tumor-bearing mice.
[0604] Although specific embodiments of the present invention have been described in detail, it will be understood by those skilled in the art that various modifications and substitutions may be made to those details in light of all the teachings disclosed herein, and such modifications are within the scope of the present invention. The full scope of the present invention is given by the appended claims and any equivalents thereof.
Claims
1. A bispecific antibody comprising a first protein functional region and a second protein functional region, in: The first protein functional region targets LAG3, The second protein functional region targets a target different from LAG3 (e.g., CD73 or PD-1), Wherein, the first protein functional region is an anti-LAG3 antibody or an antigen-binding fragment thereof, wherein the anti-LAG3 antibody comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3, and the light chain variable region comprises LCDR1, LCDR2 and LCDR3, wherein, The amino acid sequence of HCDR1 is shown in SEQ ID NO:9, The amino acid sequence of HCDR2 is shown in SEQ ID NO: 10, The amino acid sequence of HCDR3 is shown in SEQ ID NO:11; The amino acid sequence of LCDR1 is shown in SEQ ID NO: 12 or SEQ ID NO: 17, The amino acid sequence of LCDR2 is shown in SEQ ID NO: 13 or SEQ ID NO: 15, The amino acid sequence of LCDR3 is shown in SEQ ID NO:14 or SEQ ID NO:
16.
2. The bispecific antibody according to claim 1, in, The amino acid sequence of LCDR1 is shown in SEQ ID NO: 12, The amino acid sequence of LCDR2 is shown in SEQ ID NO: 13, and The amino acid sequence of LCDR3 is shown in SEQ ID NO:14; or The amino acid sequence of LCDR1 is shown in SEQ ID NO: 12, The amino acid sequence of LCDR2 is shown in SEQ ID NO: 15, and The amino acid sequence of LCDR3 is shown in SEQ ID NO:16; or The amino acid sequence of LCDR1 is shown in SEQ ID NO: 17, The amino acid sequence of LCDR2 is shown in SEQ ID NO: 15, and The amino acid sequence of LCDR3 is shown in SEQ ID NO:14; or The amino acid sequence of LCDR1 is shown in SEQ ID NO: 12, The amino acid sequence of LCDR2 is shown in SEQ ID NO: 13, and The amino acid sequence of LCDR3 is shown in SEQ ID NO:16; or The amino acid sequence of LCDR1 is shown in SEQ ID NO: 12, The amino acid sequence of LCDR2 is shown in SEQ ID NO: 15, and The amino acid sequence of LCDR3 is shown in SEQ ID NO:14; or The amino acid sequence of LCDR1 is shown in SEQ ID NO: 17, The amino acid sequence of LCDR2 is shown in SEQ ID NO: 13, and The amino acid sequence of LCDR3 is shown in SEQ ID NO:14; or The amino acid sequence of LCDR1 is shown in SEQ ID NO: 17, The amino acid sequence of LCDR2 is shown in SEQ ID NO: 13, and The amino acid sequence of LCDR3 is shown in SEQ ID NO:16; or The amino acid sequence of LCDR1 is shown in SEQ ID NO: 17, The amino acid sequence of LCDR2 is shown in SEQ ID NO: 15, and The amino acid sequence of LCDR3 is shown in SEQ ID NO:
16.
3. The bispecific antibody according to any one of claims 1 to 2, in, The heavy chain variable region of the anti-LAG3 antibody is selected from the amino acid sequences shown in SEQ ID NO: 2 and SEQ ID NO: 44, and the light chain variable region is selected from the amino acid sequences shown in SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8 and SEQ ID NO: 45; Preferably, The amino acid sequence of the heavy chain variable region of the anti-LAG3 antibody is shown in SEQ ID NO: 2, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 4; The amino acid sequence of the heavy chain variable region of the anti-LAG3 antibody is shown in SEQ ID NO: 2, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 6; The amino acid sequence of the heavy chain variable region of the anti-LAG3 antibody is shown in SEQ ID NO: 2, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 8; The amino acid sequence of the heavy chain variable region of the anti-LAG3 antibody is shown in SEQ ID NO: 2, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 45; The amino acid sequence of the heavy chain variable region of the anti-LAG3 antibody is shown in SEQ ID NO:44, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO:4; The amino acid sequence of the heavy chain variable region of the anti-LAG3 antibody is shown in SEQ ID NO:44, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO:6; The amino acid sequence of the heavy chain variable region of the anti-LAG3 antibody is shown in SEQ ID NO:44, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO:8; or The amino acid sequence of the heavy chain variable region of the anti-LAG3 antibody is shown in SEQ ID NO:44, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO:
45.
4. The bispecific antibody according to any one of claims 1 to 3, in, The anti-LAG3 antibody or antigen-binding fragment thereof is selected from Fab, Fab', F(ab')2, Fd, Fv, dAb, complementarity determining region fragment, single-chain antibody, humanized antibody or chimeric antibody.
5. The bispecific antibody according to any one of claims 1 to 4, in, The anti-LAG3 antibody includes non-CDR regions, and the non-CDR regions are from human antibodies.
6. The bispecific antibody according to any one of claims 1 to 5, in, The second protein functional region is an anti-CD73 antibody or an antigen-binding fragment thereof, wherein the anti-CD73 antibody comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises a HCDR1 with an amino acid sequence as shown in SEQ ID NO: 25, a HCDR2 with an amino acid sequence as shown in SEQ ID NO: 26, and a HCDR3 with an amino acid sequence as shown in SEQ ID NO: 27; and The light chain variable region comprises LCDR1 with an amino acid sequence as shown in SEQ ID NO:28, LCDR2 with an amino acid sequence as shown in SEQ ID NO:29, and LCDR3 with an amino acid sequence as shown in SEQ ID NO:
30.
7. The bispecific antibody according to claim 6, in, The heavy chain variable region of the anti-CD73 antibody is selected from the amino acid sequences shown in SEQ ID NO: 31, SEQ ID NO: 33, SEQ ID NO: 35 and SEQ ID NO: 46; the light chain variable region is selected from the amino acid sequences shown in SEQ ID NO: 32, SEQ ID NO: 34, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 47 and SEQ ID NO: 62; Preferably, The amino acid sequence of the heavy chain variable region of the anti-CD73 antibody is shown in SEQ ID NO:31, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO:32; The amino acid sequence of the heavy chain variable region of the anti-CD73 antibody is shown in SEQ ID NO:31, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO:34; The amino acid sequence of the heavy chain variable region of the anti-CD73 antibody is shown in SEQ ID NO:31, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO:36; The amino acid sequence of the heavy chain variable region of the anti-CD73 antibody is shown in SEQ ID NO:31, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO:37; The amino acid sequence of the heavy chain variable region of the anti-CD73 antibody is shown in SEQ ID NO:31, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO:47; The amino acid sequence of the heavy chain variable region of the anti-CD73 antibody is shown in SEQ ID NO:31, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO:62; The amino acid sequence of the heavy chain variable region of the anti-CD73 antibody is shown in SEQ ID NO: 33, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 32; The amino acid sequence of the heavy chain variable region of the anti-CD73 antibody is shown in SEQ ID NO: 33, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 34; The amino acid sequence of the heavy chain variable region of the anti-CD73 antibody is shown in SEQ ID NO: 33, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 36; The amino acid sequence of the heavy chain variable region of the anti-CD73 antibody is shown in SEQ ID NO: 33, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 37; The amino acid sequence of the heavy chain variable region of the anti-CD73 antibody is shown in SEQ ID NO:33, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO:47; The amino acid sequence of the heavy chain variable region of the anti-CD73 antibody is shown in SEQ ID NO:33, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO:62; The amino acid sequence of the heavy chain variable region of the anti-CD73 antibody is shown in SEQ ID NO: 35, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 32; The amino acid sequence of the heavy chain variable region of the anti-CD73 antibody is shown in SEQ ID NO: 35, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 34; The amino acid sequence of the heavy chain variable region of the anti-CD73 antibody is shown in SEQ ID NO: 35, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 36; The amino acid sequence of the heavy chain variable region of the anti-CD73 antibody is shown in SEQ ID NO: 35, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 37; The amino acid sequence of the heavy chain variable region of the anti-CD73 antibody is shown in SEQ ID NO:35, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO:47; The amino acid sequence of the heavy chain variable region of the anti-CD73 antibody is shown in SEQ ID NO:35, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO:62; The amino acid sequence of the heavy chain variable region of the anti-CD73 antibody is shown in SEQ ID NO:46, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO:32; The amino acid sequence of the heavy chain variable region of the anti-CD73 antibody is shown in SEQ ID NO:46, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO:34; The amino acid sequence of the heavy chain variable region of the anti-CD73 antibody is shown in SEQ ID NO:46, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO:36; The amino acid sequence of the heavy chain variable region of the anti-CD73 antibody is shown in SEQ ID NO:46, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO:37; The amino acid sequence of the heavy chain variable region of the anti-CD73 antibody is as shown in SEQ ID NO:46, and the amino acid sequence of the light chain variable region is as shown in SEQ ID NO:47; or The amino acid sequence of the heavy chain variable region of the anti-CD73 antibody is shown in SEQ ID NO:46, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO:
62.
8. The bispecific antibody according to any one of claims 1 to 7, in, The anti-LAG3 antibody or the anti-CD73 antibody further comprises a constant region, wherein the constant region is derived from a human antibody; Preferably, the constant region of the anti-LAG3 antibody or the anti-CD73 antibody is selected from the constant region of human IgG1, IgG2, IgG3 or IgG4; Preferably, the anti-LAG3 antibody comprises a heavy chain constant region and a light chain constant region, the heavy chain constant region is Ig gamma-1 chain C region (for example, as shown in SEQ ID NO: 18) or Ig gamma-4 chain C region (for example, as shown in SEQ ID NO: 20); the light chain constant region is Ig kappa chain C region (for example, as shown in SEQ ID NO: 19); Preferably, the anti-CD73 antibody comprises a heavy chain constant region and a light chain constant region, the heavy chain constant region is Ig gamma-1chain C region (e.g., as shown in SEQ ID NO: 18) or Ig gamma-4chain C region (e.g., as shown in SEQ ID NO: 20); the light chain constant region is Ig kappa chain C region (e.g., as shown in SEQ ID NO: 19).
9. The bispecific antibody according to any one of claims 1 to 8, Features Any of the following (1) to (4): (1) The anti-LAG3 antibody is of human IgG1 subtype, Wherein, according to the EU numbering system, the heavy chain constant region of the antibody has the following mutations: L234A and L235A, L234A and G237A, L235A and G237A, or L234A, L235A and G237A; (2) The anti-LAG3 antibody is of human IgG4 subtype, Wherein, according to the EU numbering system, the heavy chain constant region of the antibody has the following mutations: F234A and L235A, F234A and G237A, L235A and G237A, or F234A, L235A and G237A; (3) The anti-CD73 antibody is of human IgG1 subtype, Wherein, according to the EU numbering system, the heavy chain constant region of the antibody has the following mutations: L234A and L235A, L234A and G237A, L235A and G237A, or L234A, L235A and G237A; or, (4) The anti-CD73 antibody is of human IgG4 subtype, Wherein, according to the EU numbering system, the heavy chain constant region of the antibody has the following mutations: F234A and L235A, F234A and G237A, L235A and G237A, or F234A, L235A and G237A.
10. The bispecific antibody according to any one of claims 1 to 9, in, The bispecific antibody is in IgG-scFv format; Preferably, the first protein functional region is an immunoglobulin, and the second protein functional region is a single-chain antibody; or Preferably, the first protein functional region is a single-chain antibody, and the second protein functional region is an immunoglobulin targeting a target other than LAG3 (e.g., CD73 or PD-1).
11. The bispecific antibody according to any one of claims 1 to 10, wherein include: Targeting the first protein domain of LAG3, and Targeting the second protein domain of CD73; in, The first protein functional region is an anti-LAG3 antibody, and the anti-LAG3 antibody is an immunoglobulin, and the second protein functional region is an anti-CD73 single-chain antibody; or The first protein functional region is an anti-LAG3 single-chain antibody, the second protein functional region is an anti-CD73 antibody, and the anti-CD73 antibody is an immunoglobulin.
12. The bispecific antibody according to any one of claims 10 to 11, in, The heavy chain variable region of the immunoglobulin comprises HCDR1-HCDR3 as shown in SEQ ID NOs:9-11, respectively, and the light chain variable region comprises LCDR1-LCDR3 as shown in SEQ ID NOs:12-14, respectively, and the heavy chain variable region of the single-chain antibody comprises HCDR1-HCDR3 as shown in SEQ ID NOs:25-27, respectively, and the light chain variable region comprises LCDR1-LCDR3 as shown in SEQ ID NOs:28-30, respectively; or The heavy chain variable region of the single-chain antibody comprises HCDR1-HCDR3 whose amino acid sequences are shown in SEQ ID NOs:9-11, respectively, and the light chain variable region comprises LCDR1-LCDR3 whose amino acid sequences are shown in SEQ ID NOs:12-14, respectively, and the heavy chain variable region of the immunoglobulin comprises HCDR1-HCDR3 whose amino acid sequences are shown in SEQ ID NOs:25-27, respectively, and the light chain variable region comprises LCDR1-LCDR3 whose amino acid sequences are shown in SEQ ID NOs:28-30, respectively.
13. The bispecific antibody according to any one of claims 10 to 12, in, The heavy chain variable region of the immunoglobulin is selected from the amino acid sequences shown in SEQ ID NO:2 and SEQ ID NO:44, the light chain variable region is selected from the amino acid sequences shown in SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8 and SEQ ID NO:45, and the heavy chain variable region of the single-chain antibody is selected from the amino acid sequences shown in SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:35 and SEQ ID NO:46; the light chain variable region is selected from the amino acid sequences shown in SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:47 and SEQ ID NO:62; or The heavy chain variable region of the single-chain antibody is selected from the amino acid sequences shown in SEQ ID NO:2 and SEQ ID NO:44, the light chain variable region is selected from the amino acid sequences shown in SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8 and SEQ ID NO:45, and the heavy chain variable region of the immunoglobulin is selected from the amino acid sequences shown in SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:35 and SEQ ID NO:46; the light chain variable region is selected from the amino acid sequences shown in SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:47 and SEQ ID NO:
62.
14. The bispecific antibody according to any one of claims 10 to 13, which is selected from any one of the following (1) to (24): (1) The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 2, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 4; and, the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 31, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 32; (2) The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 2, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 4; and, the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 33, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 34; (3) The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 2, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 4; and, the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 35, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 36; (4) The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 2, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 4; and, the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 35, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 37; (5) The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 2, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 4; and, the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 46, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 47; (6) The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 2, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 4; and, the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 35, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 62; (7) The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO:44, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO:44; and, the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO:31, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO:32; (8) The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO:44, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO:45; and, the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO:33, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO:34; (9) The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO:44, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO:45; and, the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO:35, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO:36; (10) The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO:44, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO:45; and, the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO:35, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO:37; (11) The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO:44, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO:45; and, the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO:46, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO:47; (12) The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO:44, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO:45; and, the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO:35, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO:62; (13) The amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 2, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 4; and, the amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 31, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 32; (14) The amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 2, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 4; and, the amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 33, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 34; (15) The amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 2, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 4; and, the amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 35, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 36; (16) The amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 2, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 4; and, the amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 35, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 37; (17) The amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 2, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 4; and, the amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 46, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 47; (18) The amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 2, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 4; and, the amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 35, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 62; (19) The amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO:44, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO:44; and, the amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO:31, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO:32; (20) The amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO:44, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO:45; and, the amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO:33, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO:34; (21) The amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO:44, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO:45; and, the amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO:35, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO:36; (22) The amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO:44, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO:45; and, the amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO:35, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO:37; (23) The amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO:44, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO:45; and, the amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO:46, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO:47; and (24) The amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO:44, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO:45; and, the amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO:35, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO:
62.
15. The bispecific antibody according to any one of claims 1 to 14, in, The first protein functional region and the second protein functional region are independently 1, 2 or more than 2; Preferably, the first protein functional region and the second protein functional region are directly connected or connected through a linker; Preferably, the heavy chain variable region of the anti-LAG3 single-chain antibody is directly connected to the light chain variable region or connected through a linker; Preferably, the heavy chain variable region of the anti-CD73 single-chain antibody is directly connected to the light chain variable region or connected through a linker; Preferably, the linker is independently a polypeptide as shown in SEQ ID NO: 48, or a polypeptide composed of multiple (e.g., 2, 3, 4, 5 or 6) polypeptides as shown in SEQ ID NO: 48 connected in series; Preferably, the linker is independently a polypeptide having one or more glycine connected to the C-terminus of the polypeptide shown in SEQ ID NO: 48 or a polypeptide composed of multiple (eg, 2, 3, 4, 5 or 6) polypeptides shown in SEQ ID NO: 46 connected in series.
16. The bispecific antibody according to any one of claims 10 to 15, in, Each single-chain antibody is linked to the C-terminus or N-terminus of two heavy chains of immunoglobulin, respectively.
17. The bispecific antibody according to any one of claims 1 to 16, wherein include: Targeting the first protein domain of LAG3, and Targeting the second protein domain of CD73; The number of the first protein functional region is 1, and the number of the second protein functional region is 2; Wherein, the first protein functional region is an immunoglobulin, and the second protein functional region is a single-chain antibody; The amino acid sequence of the heavy chain of the immunoglobulin is shown in SEQ ID NO:38, and the amino acid sequence of the light chain thereof is shown in SEQ ID NO:39; The amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 35, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 62; or, the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 46, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 47; Each single-chain antibody is linked to the C-terminus of two heavy chains of an immunoglobulin; The first protein functional region is connected to the second protein functional region via a first linker; and the heavy chain variable region of the single-chain antibody is connected to the light chain variable region of the single-chain antibody via a second linker; the first linker and the second linker are the same or different; Preferably, the amino acid sequences of the first linker and the second linker are independently selected from SEQ ID NO: 42 and SEQ ID NO: 43; Preferably, the amino acid sequences of the first linker and the second linker are both as shown in SEQ ID NO: 43; Preferably, according to the EU numbering system, the constant region of the heavy chain of the immunoglobulin comprises the following mutations: L234A and L235A, L234A and G237A, L235A and G237A, or L234A, L235A and G237A.
18. The bispecific antibody according to any one of claims 1 to 16, wherein include: Targeting the first protein domain of LAG3, and Targeting the second protein domain of CD73; The number of the first protein functional regions is 2, and the number of the second protein functional region is 1; Wherein, the first protein functional region is a single-chain antibody, and the second protein functional region is an immunoglobulin; The amino acid sequence of the heavy chain of the immunoglobulin is shown in SEQ ID NO:40, and the amino acid sequence of the light chain thereof is shown in SEQ ID NO:41; The amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 2, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 4; or the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 44, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 45; Each single-chain antibody is linked to the C-terminus of two heavy chains of an immunoglobulin; The first protein functional region is connected to the second protein functional region via a first linker; and the heavy chain variable region of the single-chain antibody is connected to the light chain variable region of the single-chain antibody via a second linker; the first linker and the second linker are the same or different; Preferably, the amino acid sequences of the first linker and the second linker are independently selected from SEQ ID NO: 42 and SEQ ID NO: 43; Preferably, the amino acid sequences of the first linker and the second linker are both as shown in SEQ ID NO: 43; Preferably, according to the EU numbering system, the constant region of the heavy chain of the immunoglobulin comprises the following mutations: L234A and L235A, L234A and G237A, L235A and G237A, or L234A, L235A and G237A.
19. An isolated nucleic acid molecule encoding the bispecific antibody of any one of claims 1 to 18.
20. A recombinant vector comprising the isolated nucleic acid molecule of claim 19.
21. A host cell comprising the isolated nucleic acid molecule of claim 19, or comprising the recombinant vector of claim 20.
22. A pharmaceutical composition comprising the bispecific antibody according to any one of claims 1 to 18; optionally, further comprising a pharmaceutically acceptable excipient.
23. Use of the bispecific antibody according to any one of claims 1 to 18 in the preparation of a medicament for treating or preventing tumors; Preferably, the tumor is one or more selected from ovarian cancer, esophageal cancer, melanoma, hematological tumor, glioblastoma, renal cell carcinoma, lung cancer, prostate cancer, bladder cancer, colon cancer, rectal cancer, liver cancer, gastric cancer, breast cancer, brain cancer, pancreatic cancer, thyroid cancer, head and neck cancer and kidney cancer; Preferably, the lung cancer is non-small cell lung cancer; Preferably, the blood tumor is leukemia; Preferably, the esophageal cancer is esophageal squamous cell carcinoma.
24. The bispecific antibody according to any one of claims 1 to 18, for use in treating or preventing tumors; Preferably, the tumor is one or more selected from ovarian cancer, esophageal cancer, melanoma, hematological tumor, glioblastoma, renal cell carcinoma, lung cancer, prostate cancer, bladder cancer, colon cancer, rectal cancer, liver cancer, gastric cancer, breast cancer, brain cancer, pancreatic cancer, thyroid cancer, head and neck cancer and kidney cancer; Preferably, the lung cancer is non-small cell lung cancer; Preferably, the blood tumor is leukemia; Preferably, the esophageal cancer is esophageal squamous cell carcinoma.
25. A method for treating or preventing tumors, comprising the step of administering an effective amount of the bispecific antibody according to any one of claims 1 to 18 to a subject in need thereof; Preferably, the tumor is one or more selected from ovarian cancer, esophageal cancer, melanoma, hematological tumor, glioblastoma, renal cell carcinoma, lung cancer, prostate cancer, bladder cancer, colon cancer, rectal cancer, liver cancer, gastric cancer, breast cancer, brain cancer, pancreatic cancer, thyroid cancer, head and neck cancer and kidney cancer; Preferably, the lung cancer is non-small cell lung cancer; Preferably, the blood tumor is leukemia; Preferably, the esophageal cancer is esophageal squamous cell carcinoma.
